The National Development and Reform Commission (NDRC) issued a three-level warning on the excessive drop of live pig prices on the 16th, and said that it would pay close attention to the trend of live pig production and market prices with relevant departments, and timely carry out reserve adjustment to promote the smooth operation of the live pig market.

　　Recently, the price of live pigs has continued to decline due to the combined effects of concentrated slaughter of large-weight pigs, increased imports of frozen pork and weak seasonal demand. According to the prices of livestock products and feed markets in the second week of June released by the Ministry of Agriculture and Rural Affairs on the 16th, the average price of pork in China was 27.77 yuan per kilogram, down 5.7% from the previous week and 40% year-on-year. Pork prices have generally declined in 30 monitored provinces across the country.

　　According to the National Development and Reform Commission, according to the monitoring, from June 7 to 11, the national average price of pig food was 5.88 to 1, which entered the three-level early warning range of excessive decline set by the "Improving the government pork reserve adjustment mechanism and doing a good job in ensuring supply and stabilizing prices in the pork market" (hereinafter referred to as the "plan").

　　Accordingly, the National Development and Reform Commission issued a three-level warning for the excessive drop in the price of live pigs, prompting farms (households) to scientifically arrange production and management decisions and maintain the production capacity of live pigs at a reasonable level. Previously, the National Development and Reform Commission, together with the Ministry of Finance, the Ministry of Agriculture and Rural Affairs, the Ministry of Commerce, the General Administration of Market Supervision and other departments, jointly issued the "Pre-plan" to give play to the regulatory role of the government’s pork reserves, and insisted on both "raising" and "lowering" the prices of live pigs and pork, so as to ensure stable prices with stable supply and promote stable supply with stable prices. When the price is too high, reserves will be put in to protect the consumption needs of residents, push the price down to a reasonable range, and avoid excessive expansion of pig production capacity; When the price is too low, purchasing and storage will be started to support the market, which will give farmers a "reassurance" and avoid excessive elimination of pig production capacity.

　　The Ministry of Agriculture and Rural Affairs has also continuously introduced measures to guide the regional scientific planning of pig breeding layout, strengthen the connection between pig production and marketing planning, and encourage the exploration of a long-term mechanism for compensating production areas in sales areas. Actively explore the establishment of grading management system of farms, adopt differentiated management measures, explore the establishment of pig capacity reserve system, improve regulatory policies, etc., and strive to prevent pig production and price ups and downs.

The sales target of Wenjie Automobile in 2024 is 600,000 vehicles. To achieve this goal, the average monthly sales volume should reach more than 50,000 vehicles. According to the sales volume of the main models, such as the M5 and M7, and the newly listed M9, there is still a certain distance from the monthly sales of 50,000 vehicles. There is an urgent need for a medium-sized and large SUV to take on the heavy responsibility, and the previously exposed M8 came at the right time.

Not long ago, a set of road test spy photos of the M8 was released on the Internet. However, considering all aspects of information, it is very likely that this set of spy photos is an early M9 test vehicle rather than a real M8 vehicle. Pay attention to the fact that the air intake grille on the front of the spy photos has a cooling hole, which is specially designed for the heat dissipation of the range extender. Later, when the M9 went on the market, we also saw that it was consistent with the pure electric version in appearance, and all of them were changed to lower air intake.

According to online news, it is very likely that the M8 will be listed in mid-2024, with a body size closer to that of M9 and larger than that of M7. The price of the new car is predicted to start at 350,000 yuan, which will be a product in the same price range as the ideal L8. Ideal L8 sold 15,000 vehicles a month at the peak of sales last year. What did M8 do to deal with it?

First of all, in terms of configuration, the M8 is hard enough: it is equipped with 800V high-voltage battery pack, laser radar, smart lighting, AR-HUD head-up display, Turing chassis, etc., and it is possible to provide 5-seat, 6-seat or 7-seat models.

Chassis and performance are the killer of M8. It is reported that apart from the intelligent chassis of Huawei Turing, the M8 will also be equipped with its 800-volt high-voltage power system of the giant whale. The combination of these two innovative technologies will greatly improve the driving performance and charging efficiency.

After Huawei’s ADS 2.0 system is superimposed, the IP M8 can also be intelligently and adaptively adjusted by sensing hardware, including air suspension and CDC variable damping shock absorber. At that time, the performance of IP M8 in chassis handling and comfort will be even better.

On the level of intelligent driving, Huawei ADS 2.0 intelligent driving system can reach L3 level in the future, but on the M8, the hardware configuration is believed to be not too bad. The 192-line laser radar (1), millimeter-wave radar (3), door-opening anti-collision millimeter-wave radar (4), ultrasonic radar (12) and high-definition camera (11) will not fall down, and the fusion sensing BEV will identify all kinds of abnormal obstacles. Without the support of high-precision map, NCA of most urban roads can still be covered.

In terms of endurance performance, the new car is equipped with a "Whale" 800V high-voltage battery pack, which reduces the wiring harness by 80% and the thickness by 16.4%, and can charge 150 kilometers in 5 minutes. According to the M9, the extended-range version has a battery life of over 1,400 kilometers (over 200 kilometers for pure electric vehicles), and the pure electric version can also reach 630 kilometers. It is expected that the battery life performance of the M8 will not be too different.

N comments:On March 22nd, HarmonyOS Zhixing announced that 86 days after the listing of the M9, it will definitely exceed 60,000 sets. According to the current information analysis, the configuration, intelligence level, chassis, performance and hardware performance of Wenjie M8 are quite interesting. Thanks to the advantages of backwardness, its comprehensive product strength is likely to exceed the ideal L8. The remaining key is the price. At present, the ideal L8 has a discount at the terminal, and the future transaction price is likely to exceed the range of 300,000 yuan. How much does M8 sell, or it will become a key factor affecting its sales.

Original clove doctor　

A surprise inspection!

Did you have a good drink of water today?

Or are you feeling thirsty

My throat is as dry as the Sahara desert.

Under normal circumstances, adult women only need to consume 1.1 ~ 1.5 liters of water a day, and adult men only need to consume 1.2 ~ 1.9 liters of water to meet their needs (including water in drinks and food).

But! Some people need more water than this.

Image source: cover expression pack

If you eat something at ordinary times, you must have a drink.

Otherwise, it’s too dry to swallow

When sleeping at night

I’m so thirsty that I may even cough

Need to get out of bed for tons of irrigation three times and two times.

Crucially:

I also drank a lot of water, but I just couldn’t quench my thirst!

Don’t be nervous yet ~ Thirst is a normal physiological reaction of human beings. In the short term, it may be that the weather is too hot, eating too salty, and just experienced strenuous exercise.

But if you continue to feel dry mouth and have some other accompanying symptoms, be careful!

This may be a signal from some diseases: your body has several potential health problems that need to be vigilant.

Image source: Station Cool Hailuo

01

Thyroid diseases

Patients with hyperthyroidism have increased thyroid hormone secretion, accelerated basal metabolic rate and significantly increased oxygen consumption. In addition, the heat production of the body increases, the heat dissipation accelerates, and the demand for water will increase accordingly.

Make your mouth thirsty, become a buffalo, and drink more water than usual.

Hyperthyroidism patients may also be accompanied by increased heart rate, palpitation, shaking hands, diarrhea, more sweating in hands, less hair loss, etc., but the most obvious manifestation may be the thickening of the neck.

In addition, people who used to be nice have suddenly exploded like a runaway scooter recently.

I also feel that I am always upset, insomnia and anxiety, and my brain often has a party late at night, making it difficult to sleep.

In the above situation, it is best to go to the endocrinology department in time and make an appointment for thyroid function determination and ultrasound examination.

Image source: Station Cool Hailuo

02

sicca syndrome

This is a common rheumatic disease, and the common clinical manifestation is dry mouth for more than 3 months.

Say a word and eat a solid food, you need to drink water. Eyes will feel very dry, like entering the sand.

Different from "dry eye", it is an eye disease, which is caused by insufficient tear secretion or excessive evaporation. Sjogren’s syndrome is a chronic autoimmune disease.

Let’s just say it’s because your own immune organization mistakenly attacked salivary glands, lacrimal glands and other glands. These glands responsible for producing water are destroyed and the water secretion is reduced, so you feel dry mouth and eyes.

The data show that the probability of Sjogren’s syndrome patients suffering from malignant lymphoma is nearly 40 times higher than that of ordinary people. It may also affect other multiple systems of your body and have corresponding clinical manifestations:

Involving the skin, it can be manifested as itching and desquamation of the skin;

Involved in the respiratory tract, dry cough and dyspnea may occur;

Involvement of digestive system may be accompanied by abdominal distension and diarrhea;

Involving the nervous system, limb numbness and weakness, orthostatic hypotension, hyperhidrosis, hypohidrosis or anhidrosis of limb skin, memory and attention loss may occur.

There may also be systemic symptoms such as fatigue and low fever, and a few cases will show high fever, even high fever above 39℃.

Sjogren’s syndrome is generally recommended to go to the Rheumatology Immunology Department for investigation. If there is no such department, you can go to the General Internal Medicine Department for a look.

Image source: Station Cool Hailuo

03

Diabetes, poor blood sugar control

In addition to often feeling thirsty, I am particularly hungry; Frequent urination-the number of times to pee in the toilet has increased, and the amount of urination has also increased; Weight is also lost for no reason, accompanied by a sense of fatigue that is difficult to relieve.

Please pay attention to your blood sugar level! This may be the typical symptoms of diabetes: drinking more, eating more, urinating more and losing weight.

When blood sugar rises, there will be osmotic diuresis, which will lead to the reduction of water reabsorption by the kidney, and a large amount of water will be discharged from the kidney, thus making the urine volume increase abnormally. Therefore, the body is short of water, and then it feels thirsty and unconsciously wants to drink more water, which further leads to an increase in urine output and a vicious circle.

Diabetes is very common, with 11 patients in every 100 people, and most of them can’t be cured. Once they get it, they need lifelong treatment.

If you want to know your blood sugar health as soon as possible, you can go to the endocrinology department.

Image source: Station Cool Hailuo

04

sleep apnea syndrome

After waking up in the morning, I often feel that my throat is terribly dry. Don’t ignore it. Looking back, do you still snore when you sleep?

Some people are dry, while others are dry because Lao Zhang snored with his mouth open the night before.

This is not a rap or joke, obstructive sleep apnea syndrome (OSA), but also a large group of patients with dry mouth.

TA people may snore and snore when they sleep, and their breathing pauses for several seconds before they recover. Classic clinical manifestations also include: feeling suffocated when sleeping, thirsty after waking up, dizziness and headache, drowsiness during the day, and difficulty in concentration …

In contrast, dry mouth is just a minor problem.

Studies have found that it is also related to cardiovascular and cerebrovascular diseases (such as stroke), metabolic diseases and other multi-system damage. The probability of traffic accidents in patients with obstructive sleep apnea syndrome is 250% higher than that in the general population.

Image source: Station Cool Hailuo

05

diabetes insipidus

This is a relatively rare disease.

Let’s just say that we ordinary people can’t maintain normal urine output without a substance called "antidiuretic hormone". It is synthesized by the hypothalamus and stored in the pituitary gland, working silently for us.

If this mechanism is obstructed and antidiuretic hormone is deficient, it will fall into a state of "storage failure"; Or the kidney is not sensitive to this hormone, which will make you dry mouth and urinate easily, and may also excrete a lot of innocent urine.

Generally speaking, normal adults excrete about 1 ~ 2 liters of urine a day, that is, 4 ~ 6 times of urine.

If you urinate more than 4 liters in 24 hours and urinate significantly more than 6 times, and this situation lasts for more than half a month, be alert to the possibility of diabetes insipidus.

If you are really worried, you can go to the endocrinology department or nephrology department for treatment.

Image source: Station Cool Hailuo

To sum up, whether you want to see a doctor about dry mouth mainly depends on whether it lasts for more than 3 months and has affected your daily life.

If so, remember to actively seek medical treatment and check the risk of disease. Don’t delay! Don’t delay! Don’t delay! Say the important things three times.

As for friends who are usually fine and suddenly feel itchy and have a dry mouth when they see here … Don’t panic, I advise you to drink some water first. You may simply drink less water!

Image source: emoticon pack

Or, you have thoroughly investigated the possible pathological factors, and still feel dry mouth often, and don’t fall into the "hypochondriac trap". There is also a simple answer: you need to consume more water than others, so don’t worry too much.

Admit that some "problems" are like myopia. Although it is difficult to eradicate, we can still learn to live in peace with them.

This article review expert

references

[1] Yamada Y, Zhang X, Henderson MET, Sagayama H, Pontzer H, et al. Variation in human water turnover associated with environmental and lifestyle factors. Science. 2022 Nov 25; 378(6622):909-915.

Ge Junbo, Xu Yongjian, Wang Chen. Internal Medicine [M]. 9th edition. Beijing: People’s Medical Publishing House, 2018: 829-832.

Plan and make

Planning: V | Producer: Feidi

Cover image Source: Network

Original title: "Often dry mouth, don’t think that there is water shortage! May be a sign of disease "

Read the original text

Kobayashi Pharmaceutical, once "snapped up" by consumers in China, was caught in a storm of illness and death caused by health care products.

On the evening of March 27th, Kobayashi Pharmaceutical (China) Co., Ltd. issued a statement to assist Kobayashi Pharmaceutical Co., Ltd. to recall the products related to the use of red bream raw materials independently, saying that according to the announcement of Kobayashi Pharmaceutical Co., Ltd., this independent recall involved three products, none of which were listed and sold in Chinese mainland market. Some consumers in China have purchased related products through overseas cross-border platforms, overseas physical stores or other channels, and our company will actively provide assistance in product recycling.

"For products purchased from cross-border official channels, assist Kobayashi Pharmaceutical Co., Ltd. to recycle through UNQ Japan Co., Ltd.. For other consumers, it is recommended to contact the original purchase channel to return the goods. If we encounter problems and difficulties in this process, our company will actively assist and properly solve related matters from the perspective of facilitating consumers. " The statement said that the company had notified the relevant cross-border platforms on March 22, 2024, requesting them to take off the relevant products urgently, and informed all consumers to stop eating immediately as soon as possible. We will continue to inform you many times through Want Want, SMS and other channels to ensure that the information can reach every consumer. For other known platforms with related products for sale, we are contacting the platforms one by one to request that the related products be immediately removed from the shelves and that the platforms inform all consumers to stop eating immediately as soon as possible.

According to CCTV news, NHK reported that the Japanese Ministry of Health, Labor and Welfare announced the second death case after ingesting health products containing red koji from Kobayashi Pharmaceutical Company on March 26th, and the number of people admitted to hospital has increased to 106.

According to Japanese media reports on March 27th, local time, the Osaka city government of Japan ordered Kobayashi Pharmaceutical Company to recall three kinds of products, such as "red yeast cholesterol granules", because the above products received a large number of reports of health damage and death, and the Ministry of Health, Labor and Welfare thought that "it was suspected to contain harmful substances". The monascus involved was produced by Kobayashi Pharmaceutical Osaka Factory, and the company said that it may be different from the expected ingredients from mold that caused the problem.

Prior to this, on March 24th, Kobayashi Pharmaceutical China issued a recall notice to consumers of China e-commerce platform, saying that some affected products were sold to Chinese mainland through cross-border channels, and consumers could return them and get a refund. At that time, in the notice, only one item involved in the product was mentioned.

On March 27th, the reporter contacted the customer service center of Kobayashi Pharmaceutical in China as a consumer. The customer service staff said that only one product in China was added with monascus ingredients, and other products were not. Regarding the safety of health care products containing monascus ingredients, the customer service staff said: "The reply given by our agency is that we have not confirmed whether it is directly related to kidney disease at present." If consumers are worried about health risks, it is recommended to have a kidney examination on blood, and the inspection fee will be reimbursed by the company.

If there is something wrong with the kidney, can it be judged that it is related to the product? The above-mentioned customer service staff said that it depends on the doctor’s judgment. "There must be a problem if it has not been confirmed yet, so the company can’t give a reply for the time being saying that there must be a problem, or there must be no problem."

It is worth noting that there are also domestic health care products companies and pharmaceutical companies that own products containing "red yeast".

On March 27th, Luye Pharmaceutical (2186.HK) told The Paper that the raw material of the red yeast used in Xuezhikang Capsule is a special red yeast produced by Peking University Weixin Biotechnology Co., Ltd., which has independent intellectual property rights and has nothing to do with the raw materials used by Kobayashi Pharmaceutical.

Kobayashi Pharmaceutical was asked to recall three products in Japan. What is "red koji"?

The pathogenic and fatal storm of health care products containing monascus ingredients has been fermented for many days.

On March 22, Kobayashi Pharmaceutical announced that some consumers have recently developed kidney diseases after using the health products containing monascus ingredients produced by the company. Subsequently, Japanese food and alcohol manufacturers also announced the recycling of products related to red koji produced by Kobayashi Pharmaceutical.

On March 25th, Kobayashi Pharmaceutical Co., Ltd. of Japan announced that 33 people had developed kidney diseases and other abnormal health conditions after taking the health products containing monascus, and 26 of them had been hospitalized.

On March 26th, Kobayashi Pharmaceutical Company of Japan announced that a person who might continue to take health products containing monascus for about 3 years died of kidney disease in February. Taking this product is suspected to have a causal relationship with death. An investigation has been launched and people are urged not to use the product for the time being. Also on March 26th, the Japanese Ministry of Health, Labor and Welfare held a three-hour hearing on Kobayashi Pharmaceutical Co., Ltd. on the issue that the raw materials of red yeast rice may cause damage to consumers’ health.

Japanese regulatory authorities have taken measures against Kobayashi Pharmaceutical related products. According to CCTV news, citing Japan’s current affairs news agency, Japan’s Ministry of Health, Labor and Welfare has informed relevant departments in Osaka City where Kobayashi Pharmaceutical Company is headquartered to take measures such as discarding the company’s related products based on the Food Sanitation Law.

According to Japanese media reports on March 27th, local time, the Osaka municipal government of Japan ordered Kobayashi Pharmaceutical to recall three products, including "red yeast cholesterol granules". In addition, Kobayashi Pharmaceuticals of Japan has withdrawn eight kinds of monascus health products from the Japanese Consumer Hall as functional label foods for the record, including three recalled products.

According to Japanese media reports, Kobayashi Pharmaceutical also announced that "Monascus" raw materials are also supplied to 52 companies including beverage and food manufacturers. Among the "red koji" raw materials produced, 20% are used for their own products, and 80% are sold to other enterprises. According to Japanese media reports, Kobayashi Pharmaceutical has supplied raw materials of monascus to other manufacturers through trading companies since 2016, and has been used in Japanese wine and snacks. The suppliers also include enterprises in Taiwan, China.

According to CCTV news, as of the evening of 26th local time, 30 companies, including Kobayashi Pharmaceutical Company, have announced that they have independently recycled the products of Kobayashi Pharmaceutical Company’s monascus raw materials. Some consumers said that this raw material was also used in many foods, even in miso sauce. According to Japanese media reports, relevant Japanese departments will conduct emergency inspections on the safety of more than 6,000 functional foods on the market.

What is the monascus ingredient in the above health care products that may harm health?

According to an article published on February 29th, 2024 by WeChat WeChat official account "Guangdong Traditional Chinese Medicine" sponsored by Guangdong Provincial Bureau of Traditional Chinese Medicine, the traditional Chinese medicine monascus is a kind of rice koji fermented by monascus, which can be used as medicine and food. It was called Danqu in ancient times, originated in China, and has been used for more than two thousand years, and has been popularized among the people as early as the Han Dynasty. Monascus, as a microbial fermented product, can not only be used as a natural non-toxic food pigment, but also be used for antibacterial and antiseptic of meat, fish, beans and other foods. Monascus is also rich in wine fragrance, which is a good raw material for brewing vinegar.

As for the medicinal value of monascus, the above article mentioned that in the late 1970s, Japanese scientists discovered and isolated a chemical component named K(Monacolin K from monascus fermentation broth, and found that it could significantly inhibit cholesterol synthesis in the body. Monascus contains not only monacolin compounds, but also ergosterol, bioflavonoids, saponins, dietary fiber, aminoglycans and other rich physiologically active substances, which have a wide range of pharmacological effects such as lowering blood fat, lowering blood sugar, lowering blood pressure, inhibiting bacteria, resisting tumors and enhancing immunity. Flavonoids, a natural antioxidant in monascus, can protect the liver.

It should be noted that Kobayashi Pharmaceutical once said that after analyzing the components of monascus health products, it was found that some monascus raw materials may contain unknown components beyond the company’s grasp. According to this statement, it is not the monascus itself that causes patients to be admitted to hospital or die, but other unknown ingredients in the raw materials of monascus. Luye Pharmaceutical also mentioned in its response that ordinary monascus is a traditional fermented product, and the differences in strain quality, production technology and quality control management lead to different product quality and safety results.

Gu Zhongyi, director of Beijing Dietitians Association and master of public health in Tsinghua University, said that there is an active ingredient lovastatin in monascus, which can reduce the level of cholesterol in blood, but the specific dosage and effect need to be said separately. Controversially, there will be a secondary metabolite citrinin in the late fermentation of monascus, which has kidney and liver toxicity. Therefore, China has specific requirements for monascus-related products.

Gu Zhongyi stressed that if you buy health food to reduce blood fat, consult a professional or do enough homework according to your own needs, you’d better consult your doctor Yamatonokusushi first. Be sure to read the label information on the product package carefully, especially if it is not clearly marked in Chinese, be sure to consult it before eating. After using any new health food, it is best to record your feelings and symptoms, and stop consulting a doctor immediately if you feel unwell.

Kobayashi Pharmaceutical China recalled a health product containing monascus, and the company said that it could reimburse the inspection fee.

Are health products that may cause kidney disease and even death sold in China?

On March 24th, Kobayashi Pharmaceutical China issued the Notice on Stopping the Use of Red Stork Cholesterol Granules and Self-recall, saying that the company had received some reports that red Stork Cholesterol Granules, a health food manufactured and sold in Japan, might cause kidney diseases after eating it. In view of this situation, we analyzed the composition of this product and its raw materials (manufactured by Zishe), and found that some raw materials may contain unexpected ingredients. Some of the affected products are sold to Chinese mainland through cross-border channels.

Product source mentioned in Kobayashi Pharmaceutical’s China recall notice: Kobayashi Pharmaceutical China official WeChat official account.

"If you have eaten the above products and feel unwell, please consult the customer service center. At the same time, if you hold this product, please contact the customer service center, and we will explain the return and refund methods to you. " China, Kobayashi Pharmaceutical, said that if you have red herring cholesterol granules (60 capsules, barcode 4987072059708), please stop eating.

The above recall notice is for consumers of Tmall Kobayashi’s overseas flagship store, Pinduoduo’s official overseas flagship store and Kobayashi’s overseas direct sales store in JD.COM. On March 27th, a reporter from The Paper searched on the e-commerce platform. Only Tmall could find "Kobayashi’s overseas flagship store", and no health products related to monascus were on sale. However, "Pinduoduo’s official overseas flagship store" and "Kobayashi’s overseas JD.COM direct store" could not be found in Pinduoduo and JD.COM.

China of Kobayashi Pharmaceutical said, "We recognize that this is a serious problem and will continue to investigate.". However, the specific properties of this component and its correlation with kidney diseases have not yet been determined. For the purpose of protecting consumers’ health, we decided to recall the related products of red carp raw materials independently.

On March 27th, the reporter contacted the customer service center of Kobayashi Pharmaceutical in China as a consumer. The customer service staff first asked whether the user had drowsiness, turbid urine and difficulty in urination after purchasing and using this drug. After receiving the reply of "not at present", the customer service staff stressed that "the reply given by our agency is that we have not confirmed whether it is directly related to kidney disease at present". If the consumer is worried about health risks, it is suggested to have a kidney examination on blood, and the company will be responsible for reimbursement of the examination fees.

If there is a kidney problem, can it be judged that the kidney problem is related to the product? The above-mentioned customer service staff said that it depends on the doctor’s judgment. "There must be a problem if it has not been confirmed yet, so the company can’t give a reply for the time being saying that there must be a problem, or there must be no problem."

Kobayashi pharmaceutical products have been "snapped up" by consumers in China.

Kobayashi Pharmaceutical was established in Japan in 1998. Although the company name contains the word "pharmaceutical", it is not a pharmaceutical enterprise in the usual sense. According to official data, Kobayashi Pharmaceutical provides a variety of products in the fields of pharmaceuticals, fragrances, health care products and daily necessities.

Around 2015, Kobayashi’s products in Japan became the target of Japanese tourists’ "buying" in Japan, and the post "You must buy 12 kinds of magic drugs when you go to China" circulated on social networking sites included many products owned by Kobayashi. According to The Paper’s previous report, Kobayashi Pharmaceutical gave people the impression that it was developing the daily necessities production of unique commodities in a Niche Market. Kobayashi Pharmaceutical was rated as an "inbound consumer brand" by the Japanese capital market, and the company’s share price also rose. In 2015, the annual growth rate of Kobayashi Pharmaceutical’s share price reached 40%.

Japanese media reported that the recalled red carp cholesterol granules are said to have the effect of reducing harmful cholesterol values, with annual sales of 600 million yen. The recalled products have been sold in pharmacies in Japan since 2021, with a cumulative sales volume of nearly 1.1 million copies.

Under the influence of the recent turmoil, Kobayashi Pharmaceutical’s share price plummeted, closing down 16.51% on 25th, slightly rising on 26th and closing down 3.83% on 27th.

Part of the products sold by Kobayashi Pharmaceutical in China Source: official website screenshot

In China, Kobayashi’s activities can also be traced back to 1998: Kobayashi Pharmaceutical Co., Ltd., Shanghai Friendship Group and Benfeng Development Co., Ltd. of Hong Kong Special Administrative Region established Shanghai Kobayashi in Minhang, Shanghai. Official website data show that in 1999, the company began to produce and sell domestic colloidal aromatic products. In 2002, Kobayashi Pharmaceutical Co., Ltd. of Japan acquired the shares of Shanghai Friendship Group and Benfeng Development Co., Ltd. of Hong Kong Special Administrative Region, established a wholly-owned company, and changed its name to "Shanghai Kobayashi Daily Chemical Co., Ltd.". In 2023, Kobayashi Pharmaceutical China absorbed and merged with Shanghai Kobayashi Daily Chemical.

According to Tianyancha App, Kobayashi Pharmaceutical Co., Ltd. has invested in three companies in Chinese mainland, including Kobayashi Pharmaceutical (China) Co., Ltd., Hefei Kobayashi Pharmaceutical Co., Ltd. and Shanghai Kobayashi Pharmaceutical Trading Co., Ltd., among which the first two companies are still in existence. Kobayashi Pharmaceutical (China) Co., Ltd. invested in Hefei Kobayashi Commodity Co., Ltd. and Jiangsu Kobayashi Pharmaceutical Co., Ltd., and set up branches in Beijing, Shanghai and Guangzhou.

By category, the products currently sold by Kobayashi Pharmaceutical in China include warm stickers, antipyretic stickers, deodorant, personal care, cleaning products, oral care, disinfectants and so on.

Clarification of domestic drugs and health products: the use of red yeast in products has nothing to do with Kobayashi Pharmaceutical.

It is not a company of Kobayashi Pharmaceutical to use monascus for health care products. The reporter found through wind search that many health care products or pharmaceutical companies such as Tomson Bianjian, Qidi Pharmaceutical, Shouxian Valley and Luye Pharmaceutical have "monascus" related products.

Qidi Pharmaceutical (000590) mentioned in the reply in January 2024 that the registered health food of the company for delaying aging includes red koji soybean isoflavone tablets; At the end of 2023, Shouxiangu (603896) announced that its wholly-owned subsidiary Jinhua Shouxiangu Pharmaceutical Co., Ltd. had completed the registration of domestic health food. Chenguang Bio (300138) mentioned in the semi-annual report of 2023 that the company has the health food registration approval certificate of Caizhiyuan Ginkgo biloba red yeast capsule.

In addition to health care products, there are also pharmaceutical companies involved in monascus-related business. Qianyuan Pharmaceutical has the patent of "a red yeast fermentation device", the application date is April 22, 2022, and the validity period is 10 years.

Xuezhikang of Lvye Pharmaceutical Co., Ltd. is made from red yeast rice and used for the treatment of hyperlipidemia. Regarding the safety of the monascus ingredients in Xuezhikang, Luye Pharmaceutical emphasized that compared with ordinary monascus, Xuezhikang’s raw materials are strictly screened monascus strains, and the production process is strictly controlled. The company conducts regular monitoring according to the requirements of regulatory laws and regulations, and all testing indicators meet the relevant national drug safety management standards, and no unqualified conditions are found. Xuezhikang capsule has been approved for marketing since 1995. A large number of safety research evidences and clinical application data in the past 30 years have fully proved its effectiveness and safety, and the company will continue to carry out safety research, monitoring and analysis of Xuezhikang products. Patients can safely use this product under the guidance of a doctor.

Cctv news(Reporter wanglili) According to the latest data released by the Ministry of Public Security, from January to September 2021, 262,000 cases of telecommunication network fraud were cracked and 373,000 suspects were arrested, up by 41.1% and 116.4% respectively. In 2020, 927,000 cases of telecommunication network fraud were filed nationwide, which caused losses of 35.37 billion yuan to the masses.

In response to the telecommunication network fraud crime that the public hates, the state has "released a big move". Recently, the draft anti-telecommunication network fraud law was published and publicly solicited opinions from the public. This is the first time that China has made special legislation to combat and control telecommunication network fraud, marking the official entry of anti-telecommunication network fraud crime into the national legislative process. During the interview, it is obvious that with the joint efforts of public security organs, financial institutions, technology companies and other industries in the whole society, a war of "attack" and "prevention" against telecom fraud is about to start.

Public security organs: cases continue to be high, and the network black and gray industry continues to expand.

In daily life, netizens who are short of funds are defrauded by loans; Frequent online shopping is impersonated as customer service and false shopping fraud; Those who can’t find a job are defrauded by part-time brushing … … During the interview, the police officer of Taiyuan Anti-fraud Center said that taking the case data of Taiyuan City as an example, telecommunication network fraud cases continued to be high, accounting for more than 40% of criminal cases. Among them, loans, brushing bills, killing pig plates and impersonating customer service are high-incidence cases.

It is understood that the total number of such cases is rising, criminal gangs are becoming more specialized and collectivized, the division of labor is gradually refined, and the activity area is cross-border, gradually forming a complete chain of upstream and downstream links. The most serious thing is that the black and gray industries such as providing citizens’ personal information, building network platforms and transferring funds channels for fraud gangs are expanding.

In Shanxi, Taiyuan Public Security Bureau continued to carry out the "card-breaking" operation, and successively destroyed a large number of domestic fraud dens and black ash gangs, and arrested a large number of cross-border fraud suspects who returned to China from abroad; We rolled out early warning and prevention work in an all-round way, continued to strengthen accurate early warning and dissuasion work, and successfully prevented a large number of people from being deceived.

Financial institutions: Opening accounts in different places, tightening innovation and launching "account security lock"

In the bank, the staff are promoting how to prevent fraud to the elderly.

Previously, news such as "bank staff at the counter urged the old lady not to transfer money" frequently appeared in hot searches. According to the Report on Mobile Phone Security in China in 2020 released by China Information and Communication Research Institute, although there were more people cheated after 1990s, the per capita loss was low. Once the post-60 s fall into the online scam, the per capita loss exceeds 20,000 yuan.

Among many leaked information, bank cards and mobile phone cards are the two core "realized" hardware. According to the relevant work requirements of the state on strengthening the crackdown on cross-border gambling and power grid fraud, the central bank clearly stipulates the main responsibility of "whoever opens an account is responsible". Therefore, many individual users and small and micro business owners find it difficult to open an account in a bank recently.

When visiting major banks in Shanxi, the reporter found that in order to prevent and control risks, many banks are more strict with card opening users. When establishing diplomatic relations with five major banks in Taiyuan, reporters were asked to open accounts as individual customers, and they were all asked "whether they are local accounts" at the first time. When they were sure, the staff of the outlets said that they could open accounts directly with their ID cards; If not, many bank staff will further ask about the specific purpose of card opening.

Among them, for individuals to open accounts in different places, the staff of Industrial Bank and Jinshang Bank not only repeatedly asked about the purpose of opening the card, but also requested to submit the red book containing their names or the supporting documents such as unit certificates or lease contracts.

In response to this phenomenon, the central bank recently issued "Guiding Opinions on Doing a Good Job in Personal Bank Account Services for Floating Employment Groups" and "Guiding Opinions on Doing a Good Job in Bank Account Optimization Services and Risk Prevention and Control for Small and Micro Enterprises", clearly stating that it is necessary to strengthen the optimization of account services and account management while not reducing the convenience of account opening and risk prevention and control.

During the interview, many professionals said that financial institutions need to constantly optimize and refine account opening control measures and constantly innovate their working methods in preventing and controlling network telecom fraud. Wang Fei, the retail finance department of Minsheng Bank Taiyuan Branch, said that taking their bank as an example, a sound financial business due diligence system has been established for the number of financial accounts and abnormal cards; Innovatively launch a full "account security lock" on the client; Open up a green channel for customers who actively cancel redundant bank cards, give various forms of encouragement, and fulfill the social responsibility of banks.

Technology company: the anti-fraud strategy needs to be improved urgently for fingerprint authentication.

Since 2021, there have been 2,700 cases of telecommunication network fraud in China, with an average daily loss of 140 million yuan. Although financial institutions are "strictly guarding against death", under the temptation of huge interests, criminal organizations still hold many black technologies, which bring many risks to all industries.

Nowadays, online fraud methods emerge in an endless stream. Many "black" technologies use the loopholes in the mobile phone system to crack fingerprint authentication, wear special glasses or make up to break through face recognition and live verification.

During the interview, Fu Liting, Marketing Director of Public Security Business Group of Iflytek Smart City Business Group, said that relying on core technologies such as voice recognition and intention recognition, they can quickly, accurately and comprehensively discover sensitive and harmful information spread in the telecommunication network, and timely push warning clues to the public security anti-fraud center for landing interception. In addition, instead of traditional manual lines, anti-fraud dissuasion robots are used to timely, automatically and accurately complete anti-fraud dissuasion work such as outgoing calls, publicity and intervention, accurately screen potential victims, and assist police officers in handling massive police situations.

In addition, many people in the industry believe that the current financial system urgently needs to improve the anti-fraud strategy. By collecting, cleaning and processing user behavior data, accurate portraits can be realized, user behavior scoring models can be established, and real-time and quasi-real-time monitoring and prevention of transactions can be realized through machine learning.

Legal expert: the anti-fraud atmosphere of the whole society is gradually taking shape

Telecom fraud has become a prominent crime with the highest incidence, the greatest loss and the strongest response from the masses. For the first time, China has made special legislation on telecom fraud. Wang Jijun, a professor at Shanxi University Law School, said that the anti-fraud atmosphere of the whole society is gradually taking shape. According to the requirements of improving the preventive legal system, the draft will strengthen the construction of preventive system measures for all aspects of telecom network fraud, such as information chain, capital chain, technology chain and personnel chain, so as to provide legal support for the actual needs of overall development and security, maintaining social management order and ensuring people’s property safety.

In his view, the draft is a preventive legislation. After the anti-telecommunication network fraud law enters the law, the definition, law enforcement, confirmation and sentencing of such fraud will be clearly based on the law, and the powers and responsibilities of public security organs and judicial departments to crack down on telecommunication network fraud crimes will be clearer, which is of great significance to maintaining social stability and economic and social development.

　　Too rustic, too superficial and too vulgar are the main reasons why short videos are frequently criticized. When short videos become the mainstream mode of information dissemination, users don’t want to be surrounded by invalid information or abandoned by the times. It is necessary to choose the one with attitude and not kitsch among hundreds of short video apps.

　　

　　The most popular short video apps can be divided into tool-based and social-based apps. Tool-based short video apps have tall shooting and editing tools, including various filters, multi-lens editing, sticker animation, background music and other functions, allowing users to shoot movie-like videos on their mobile phones through simple operations. For example, to draw videos, interesting tweets, etc., these apps meet the shooting needs of non-professionals in different scenes through the video editing tools on the tall. Of course, they also have social functions such as "work sharing", but they pay more attention to "tools" than "socialization" compared with their users. Social short video apps pay more attention to video viewing and sharing. The main types are PGC (professional production content), UGC (user-generated content) and PUGC (professional user-generated content or expert-produced content), which record and share the wonderful moments in life through simple shooting and editing. Tik Tok, Aauto Quicker and Watermelon are this type of apps, and their contents can be basically divided into five sections: street visiting passers-by, funny spitting, life, film and television, and personal talent.

　　The differentiation of product styles of short video apps leads to a dilemma in the market structure. Short video apps with powerful video production functions lack a platform that can spread in a large area, while social short video apps with a huge user base have the problems of high cost and difficulty in making excellent videos. So is there a short video App on the market that can integrate perfect functions and powerful influence?

　　Hip-hop video, an App—— that upholds the concept of "the more you share, the happier you are", has entered the market strongly under such urgent demand, making the technical hard power and the influence of fans perfectly unified, and with its unique gameplay mechanism, it is about to subvert market cognition.

　　

　　As the main position of hip-hop video, the short video section not only has the effect of not losing to the professional shooting and editing App, but also is simpler and easier to understand. It can be done as soon as you think about it, and the one-button setting perfectly presents the video color enhancement effect. What’s more worth mentioning is that the short video section has the function of recording MV for a long time. Every lyric and every picture can be expressed at will, interpreted as much as possible, and made into a complete memory without restriction. And while sharing the happy time, you will also get the attention, praise and even reward from friends or strangers.

　　Hip-hop videos can show their own platforms, not only for recording and sharing, but also for playing hip-hop live broadcast, so that every ordinary person with a hot heart and dreams can get a customized stage. In addition to all the functions of other similar live broadcast platforms, the anchor can also convene a fan group for large-scale interaction. And VR technology will be applied to live broadcast in the later stage. No matter whether the live broadcast content is life entertainment or commercial promotion, it can make the live broadcast get rid of the constraints of space and create a real and strong sense of live interaction among fans.

　　Originally, I could rely on face value, but I like to rely on talent. The hip-hop song room section in the hip-hop video App makes your musical talent targeted. Your singing or Rouman’s euphemistic applause, or deep and restrained memories, can not only make the audience focus on you, but also perform with friends, and also have the function of real-time recording of singing. Let your musical talent not be buried in the hip-hop studio.

　　The 5G era is coming, are you still chatting with others with expression packs? Wake up! Coming to hip-hop chat rooms, real-time voice conversations, and telling jokes in person are far more attractive than pasting them in the dialog box. You can meet interesting souls and meet like-minded friends here. It is not only a place for people with the same interests to chat, but also a private place for business negotiations.

　　

　　Where there are people, there are rivers and lakes, and this sentence is also applicable in the virtual world. It is not necessarily a long-term solution to wander alone in the rivers and lakes. Hip-hop family plate, so that you can find a home alone. A group of young people with the same preferences, values and mutual appreciation create a big family of their own. Gathering popularity, sharing works, helping each other to improve income, like-minded will be more valuable!

　　Although having money can’t buy time, it’s always irresistible to use happy time to get benefits. Hip-hop video adopts the profit sharing model of members, and the relationship between members will become closer. Members adopt sharing links, invite their friends to become members through unique invitation codes, and bind themselves. When binding members pay fees, members who send invitations will enjoy the platform reward policy, which will make members more willing to share, and the more they share, the happier they will be.

　　

　　Rejecting vulgarity, hip-hop video will bring users a refreshing and ultimate experience with full positive energy! Short video, live broadcast, karaoke room, multi-player voice chat room and hip-hop family meet the needs of all kinds of people. At the same time, we should dig deep into industry resources, accurately find the pain points of senior players, and gather short video, live broadcast, social interaction, e-commerce and other functions ready to go! Hip-hop video, subvert your perception of traditional short video App, and get ready for a heat wave in the short video industry!

　　Hip-hop video, the more you share, the happier you are.

　　Disclaimer: The purpose of reprinting this article by China Youth Network is to convey more information, and it does not represent the views and positions of this website. The content of the article is for reference only and does not constitute investment advice. Investors operate accordingly at their own risk. )

　　Cctv newsRecently, on social media and some new media platforms, people often find that every time some users publish ordinary content, the number of views or likes they get can easily exceed one million, ten million or even hundreds of millions. So, how true are these figures?

　　Not long ago, Weibo, a video promoting a new song released by an artist user, received more than 100 million reposts. At present, the total number of users in Weibo, China is 337 million, which is equivalent to one in every three users in Weibo who forwarded this content.

　　journalist: How is this data defined?

　　Cao Yongshou, president of a data company in BeijingThat is, it was not painted by a real person, but by a machine (using software) manually.

　　According to Mr. Cao’s prompt, the reporter entered the name of Sina Weibo on an e-commerce platform, and the system gave priority to a large number of business options to help users increase fans or increase data. These so-called merchants recommended packages with different needs to reporters. Basically, for 10 yuan, you can buy 400 fans, or you can forward them to Weibo for 100 times. Can also be based on demand, to achieve the degree of fan activity and regional authenticity of the special customization.

　　In order to convince reporters that the data revision is true and effective, the seller claims that many artists and online celebrity have come to buy from them and have a long-term cooperative relationship with them. When the reporter tried to ask the specific artist’s name, the seller said it was inconvenient to disclose relevant information to the reporter.

　　The reporter also searched in the search engine with "traffic" as the key word, and found that 23 of the top 100 results were third-party software and platforms related to brushing traffic, providing brushing services covering almost all popular platforms. The reporter tried to download one of the softwares with the functions of "creating fans" and "creating forwarding", and filled a Weibo account that had not been updated recently into the designated location, and paid 11.92 yuan for enough points by scanning the code, and entered the target values of 500 fans and 300 forwarding times respectively. After a few minutes of operation, I found that followers with the same name were constantly pouring into the account. Similarly, a Weibo published a few days ago will be immediately forwarded by unknown users. The operation results can achieve data tampering according to the number of users’ wishes.

　　In the chat group of WeChat and Weibo, the reporter also found a lot of information about openly recruiting so-called likes. The reporter applied to join one of the chat groups as a candidate, and the administrator named "cash cow for receiving teachers" simply asked the reporter’s age and available time, and sent a job request to the reporter — — Add attention and praise to the designated customer’s Tik Tok account, and you can get a reward ranging from 1-3 yuan if you complete it. There is no upper limit on the workload per day, and wages can also be settled on the same day.

　　Cao Yongshou, president of a data company in BeijingThe water army has several characteristics. One is that you will find that the contents made by the water army are almost the same. The second is that many naval forces are online in the early hours of the morning. Do you think this is normal? If there are 10,000 fans, each person has registered 10 white numbers, and each white number sends 100 messages or messages every day, that is 100,000 times 100, and one thousand (ten thousand) can be reached in one day. In fact, it is only 10,000 people.

　　"Fans" irrational idolize boosts the proliferation of fake data

　　When data fraud becomes easy, it is inevitable to be abused. Fans who are keen on talent shows and crazy about idolize have hired the Water Army to brush the list of idols they support, and artists’ agencies and some new media platforms have also taken a fancy to the business opportunities, adding fuel to the fire behind them.

　　In order to concentrate on supporting common idols, the Star Weibo Data Station, which was set up spontaneously by fans or arranged by brokerage companies, came into being. According to Xiao Yu, a student who once participated in the list-making at the data station, personal forwarding artist Weibo can only be regarded as a daily check-in task. It has long been a common practice among fans to spend money on data for rapid increment.

　　In order to save manpower and time, fans will also share mobile phone applications that provide automatic list brushing function, enter their homepage and choose their favorite stars. No matter the date of list playing or the copy, all fans need to do is pay.

　　Breaking the myth of traffic and attracting people with works

　　For the inflated data, experts say that data fraud not only damages the basic principle of honesty between people, but also makes the performing arts market fall into a vicious circle of not paying attention to quality but only traffic.

　　Internet expert Wu Chunyong: Traffic fraud basically violates the principle of honesty. Its essence is actually to pursue the maximization of its own interests. Take different ways to brush according to the so-called demand. Such an unhealthy industrial chain and ecological chain gradually formed.

　　When data fraud becomes an industry, everyone involved in it contributes to the continuous spread of fraud more or less because of their own profits.

Professor Zhou Xing, School of Art and Media, Beijing Normal University

　　Professor Zhou Xing, School of Art and Media, Beijing Normal UniversityThe eyeball economy is a phenomenon that is hard to avoid in this era. When we communicate with stars or brokers in the industry, they certainly have a reasonable reason. When the star traffic is large, his exposure rate will be more concerned by advertisers. It is inevitable that fans will be encouraged to create traffic in clusters. But there is also a very important problem that media organizations also need interests, and when they find it easier to appeal to this emotion, they will attract attention. Creating traffic stars must be the result of the joint efforts of the three.

　　In this regard, experts called for, on the one hand, in addition to the market and relevant departments to increase supervision, fan groups, performing arts markets and platforms all need to reflect. If we only pursue immediate interests and give up creating truly valuable and quality works of art, the so-called traffic data will be nothing more than a passing cloud.

　　Professor Zhou Xing, School of Art and Media, Beijing Normal UniversityBecause it is fleeting, network communication will soon be out of sight. Young people grow up, and soon there will be new hot spots (appearing). Of course, there must be policies to curb these manufacturing institutions. Besides, it is necessary to have a positive tool of propaganda and public opinion to pay attention to the good things that are truly exemplary people, the backbone of our society, and firmly promote the development of our social economy and culture, and let young people accept them and make them become a model that is really not short-term but long-term. I think this is the important thing.

　　Qingdao, January 2 (Reporter Wang Wei) China’s new generation of marine comprehensive scientific research ship "Science" returned to Qingdao’s home port this morning (2 nd) after completing the 2016 tropical western Pacific comprehensive investigation voyage.

　　This voyage successfully maintained and upgraded China’s western Pacific submarine observation network, and successfully realized the real-time transmission of deep-sea observation data for the first time. Scientists can grasp the dynamic state of the ocean in real time in the office, changing the previous situation that submarine observation data can only be recovered once a year, and successfully cracked this world-class ocean observation problem.

　　This voyage lasted for 54 days, with a voyage of more than 7,800 nautical miles. Eleven sets of deep-sea submersibles and more than 300 pieces of observation equipment deployed in this sea area in 2015 were successfully recovered, and 14 sets of deep-sea submersibles and more than 440 pieces of observation equipment were redeployed, once again setting a new world record for the largest number of observation equipment deployed and recovered in a single voyage.

　　Researcher Wang Fan, the project leader, secretary of the Party Committee and deputy director of the Institute of Oceanography of China Academy of Sciences, said that in 2016, the project organized the Institute of Oceanography and the Institute of Acoustics of China Academy of Sciences and other units to jointly carry out the technical research on real-time transmission of deep-sea submarine data, and developed two schemes of wireless underwater acoustic communication and wired data transmission, which can collect deep-sea observation data in real time and transmit them back to the shore-based office via satellite. In this voyage, the above two schemes have been successfully implemented. Real-time transmission of data will accelerate the improvement of China’s marine operational forecasting system and the output of scientific research results, and will certainly improve China’s marine environment and climate forecasting ability.

　　"We have established a young and promising scientific research team. Through the statistical analysis of the big data of voyage surveys in the past three years, we have quantitatively evaluated various engineering and technical indicators to guide the scientific planning of voyages, the optimal design of submarine targets and the reasonable arrangement of operations, and establish a set of effective scientific workflows for the construction and maintenance of observation networks, which will provide a demonstration for the construction of ocean observation networks in China." Wang Fan introduced.

　　According to reports, the 2016 comprehensive expedition voyage to the western Pacific Ocean is a part of the strategic pilot science and technology project "Material and Energy Exchange in Tropical Western Pacific Ocean System and Its Impact" of China Academy of Sciences. The survey content has achieved full coverage of multi-disciplines, multi-scales and multi-layers, with more emphasis on the observation of the ocean at a depth of 1,000 meters, and more emphasis on the fine observation of the whole water layer mixed with small-scale turbulence in the ocean, so as to fully serve the national strategy of going deep into the sea. Through the maintenance and optimization of observation network equipment, the vertical resolution of ocean current observation in the upper ocean has reached 8 meters, the vertical resolution of ocean current and temperature observation in the deep ocean has reached 500 meters, and the time resolution of all observation elements has reached 1 hour.

　　After more than three years of independent construction by Chinese scientists, the submarine observation network of the western Pacific successfully obtained the data of temperature, salinity and ocean current in the representative sea area of the tropical western Pacific for 2-3 years, which will provide valuable data for Chinese scientists to explore and study the three-dimensional structure of the tropical western Pacific circulation, the variation of warm pool and its impact on climate change in China. With the continuous accumulation of observation network data year by year, the supporting role for scientists to study and interpret the deep ocean will increase exponentially.

(Adopted at the 11th meeting of the 13th the NPC Standing Committee on June 29th, 2019)

Catalogue

　　Chapter I General Principles

　　Chapter II Vaccine Development and Registration

　　Chapter III Vaccine Production and Batch Issuance

　　Chapter IV Vaccine Circulation

　　Chapter V Vaccination

　　Chapter VI Monitoring and Handling of Abnormal Reaction

　　Chapter VII Post-marketing Management of Vaccines

　　Chapter VIII Safeguard Measures

　　Chapter IX Supervision and Administration

　　Chapter X Legal Liability

　　Chapter XI Supplementary Provisions

Chapter I General Principles

　　Article 1 This Law is formulated in order to strengthen vaccine management, ensure vaccine quality and supply, standardize vaccination, promote the development of vaccine industry, safeguard public health and safeguard public health safety.

　　Article 2 This Law shall apply to the development, production, circulation, vaccination and supervision and management of vaccines in People’s Republic of China (PRC). Where there are no provisions in this Law, the provisions of laws and administrative regulations such as the Drug Administration Law of People’s Republic of China (PRC) and the Law of People’s Republic of China (PRC) on the Prevention and Control of Infectious Diseases shall apply.

　　The term "vaccine" as mentioned in this Law refers to preventive biological products used for human immunization in order to prevent and control the occurrence and epidemic of diseases, including immunization planned vaccines and non-immunization planned vaccines.

　　Article 3 The state implements the strictest management system for vaccines, and adheres to safety first, risk management, whole-process control, scientific supervision and social co-governance.

　　Article 4 The State adheres to the strategic and public welfare nature of vaccine products.

　　The state supports basic and applied research on vaccines, promotes vaccine research and innovation, and incorporates vaccine research, production and storage for preventing and controlling major diseases into the national strategy.

　　The state formulates development plans and industrial policies for the vaccine industry, supports the development and structural optimization of the vaccine industry, encourages large-scale and intensive vaccine production, and continuously improves the vaccine production technology and quality level.

　　Article 5 The holder of a vaccine marketing license shall strengthen the quality management of the vaccine throughout its life cycle and be responsible for the safety, effectiveness and quality controllability of the vaccine.

　　Units and individuals engaged in vaccine development, production, circulation and vaccination activities shall abide by laws, regulations, rules, standards and norms, ensure that the information in the whole process is true, accurate, complete and traceable, assume responsibilities according to law and accept social supervision.

　　Article 6 The State implements an immunization planning system.

　　Residents living in China have the right to vaccinate the EPI according to law and fulfill the obligation to vaccinate the EPI. The government provides free immunization program vaccines to residents.

　　The people’s governments at or above the county level and their relevant departments shall ensure that school-age children are vaccinated with immunization programs. The guardian shall ensure that school-age children are vaccinated with EPI vaccine on time according to law.

　　Article 7 The people’s governments at or above the county level shall incorporate vaccine safety and vaccination into the national economic and social development plan at the corresponding level, strengthen the capacity building of vaccine supervision and management, and establish and improve the working mechanism of vaccine supervision and management.

　　The local people’s governments at or above the county level shall be responsible for the supervision and administration of vaccines in their respective administrative areas, and uniformly lead, organize and coordinate the supervision and administration of vaccines in their respective administrative areas.

　　Article 8 The drug supervision and administration department of the State Council is responsible for the supervision and administration of vaccines throughout the country. The competent department of health in the State Council is responsible for the supervision and management of national vaccination. Other relevant departments in the State Council are responsible for the supervision and management related to vaccines within their respective responsibilities.

　　The pharmaceutical supervisory and administrative departments of the people’s governments of provinces, autonomous regions and municipalities directly under the Central Government shall be responsible for the supervision and administration of vaccines in their respective administrative areas. The departments responsible for drug supervision and administration of the people’s governments at the municipal and county levels with districts (hereinafter referred to as the drug supervision and administration departments) shall be responsible for the supervision and administration of vaccines in their respective administrative areas. The competent health department of the local people’s government at or above the county level shall be responsible for the supervision and administration of vaccination in this administrative region. Other relevant departments of the local people’s governments at or above the county level shall be responsible for the supervision and administration of vaccines within their respective functions and duties.

　　Article 9 the State Council and the people’s governments of provinces, autonomous regions and municipalities directly under the Central Government shall establish departmental coordination mechanisms to coordinate the work related to vaccine supervision and management, regularly analyze the vaccine safety situation, strengthen vaccine supervision and management, and ensure vaccine supply.

　　Article 10 The State implements the whole-course electronic traceability system for vaccines.

　　The drug supervision and administration department of the State Council shall, jointly with the health authorities of the State Council, formulate unified standards and norms for vaccine traceability, establish a national collaborative platform for vaccine electronic traceability, and integrate the traceability information of the whole process of vaccine production, circulation and vaccination to realize vaccine traceability.

　　The holder of the vaccine marketing license shall establish a vaccine electronic traceability system, which is connected with the national vaccine electronic traceability collaborative platform, so as to realize the traceability and verifiability of the vaccine in the smallest packaging unit in the whole process of production, circulation and vaccination.

　　Disease prevention and control institutions and vaccination units shall truthfully record vaccine circulation and vaccination according to law, and provide traceability information to the national vaccine electronic traceability collaborative platform in accordance with regulations.

　　Article 11 In the process of vaccine development, production and inspection, we should establish and improve the biosafety management system, strictly control biosafety risks, strengthen biosafety management of pathogenic microorganisms such as bacterial strains, protect the health of operators and the public, and ensure that the use of pathogenic microorganisms such as bacterial strains is legal and legitimate.

　　The history, biological characteristics and generations of bacterial strains and cell strains used in vaccine development, production and inspection shall be clearly defined, and detailed files shall be established to ensure that the sources are legal, clear and traceable; Where the source is unknown, it shall not be used.

　　Article 12 People’s governments at all levels and their relevant departments, disease prevention and control institutions, vaccination units, vaccine marketing license holders and vaccine industry associations shall regularly carry out publicity, education and popularization of vaccine safety laws, regulations and vaccination knowledge through activities such as National Children’s Vaccination Day.

　　The news media should carry out public welfare publicity on vaccine safety laws, regulations and vaccination knowledge, and supervise vaccine violations by public opinion. Publicity and reporting on vaccines should be comprehensive, scientific, objective and fair.

　　Thirteenth vaccine industry associations should strengthen industry self-discipline, establish and improve industry norms, promote the construction of industry credit system, guide and urge members to carry out production and operation activities according to law.

Chapter II Vaccine Development and Registration

　　Article 14 The state shall, according to the epidemic situation of diseases, the immune status of the population and other factors, formulate relevant research and development plans, arrange necessary funds, and support the research and development of new vaccines such as multiple vaccines and multiple vaccines.

　　The state organizes vaccine marketing license holders, scientific research institutions and medical and health institutions to jointly tackle key problems and develop vaccines urgently needed for disease prevention and control.

　　Article 15 The State encourages vaccine marketing license holders to increase investment in research and innovation, optimize production technology, improve quality control level and promote vaccine technology progress.

　　Sixteenth to carry out clinical trials of vaccines shall be approved by the drug supervision and administration department of the State Council according to law.

　　Clinical trials of vaccines shall be carried out or organized by tertiary medical institutions or disease prevention and control institutions at or above the provincial level that meet the requirements set by the drug supervision and administration department of the State Council and the health authorities of the State Council.

　　The state encourages qualified medical institutions and disease prevention and control institutions to carry out clinical trials of vaccines according to law.

　　Article 17 An applicant for a vaccine clinical trial shall formulate a clinical trial plan, establish a clinical trial safety monitoring and evaluation system, carefully select the subjects, reasonably set the subjects’ groups and age groups, and take effective measures according to the degree of risk to protect the legitimate rights and interests of the subjects.

　　Eighteenth to carry out clinical trials of vaccines, the written informed consent of the subjects shall be obtained; If the subject is a person without civil capacity, he shall obtain the written informed consent of his guardian; If the subject is a person with limited capacity for civil conduct, he shall obtain the written informed consent of himself and his guardian.

　　Nineteenth vaccines listed in China shall be approved by the drug supervision and administration department of the State Council and obtain the drug registration certificate; To apply for vaccine registration, true, sufficient and reliable data, materials and samples shall be provided.

　　The State Council pharmaceutical supervisory and administrative department shall give priority to the review and approval of vaccines and innovative vaccines urgently needed for disease prevention and control.

　　Twentieth to deal with major public health emergencies in urgent need of vaccines or other vaccines identified by the health authorities in the State Council, the benefits outweigh the risks, the drug supervision and administration department of the State Council can conditionally approve the application for vaccine registration.

　　In case of particularly serious public health emergencies or other emergencies that seriously threaten public health, the health authorities in the State Council put forward suggestions for emergency use of vaccines according to the needs of prevention and control of infectious diseases, which can be used urgently within a certain scope and time limit with the consent of the drug supervision and administration department in the State Council.

　　Twenty-first the State Council pharmaceutical supervisory and administrative departments shall, when approving the application for vaccine registration, approve the production technology, quality control standards, instructions and labels of the vaccine.

　　The drug supervision and administration department of the State Council shall timely publish the contents of vaccine instructions and labels on its website.

Chapter III Vaccine Production and Batch Issuance

　　Article 22 The State implements a strict access system for vaccine production.

　　To engage in vaccine production activities, it shall be approved by the pharmaceutical supervisory and administrative department of the people’s government at or above the provincial level and obtain a pharmaceutical production license.

　　To engage in vaccine production activities, in addition to meeting the requirements of drug production activities stipulated in the Drug Administration Law of People’s Republic of China (PRC), the following conditions shall also be met:

　　(1) Having a moderate scale and sufficient production capacity reserve;

　　(2) Having systems, facilities and equipment to ensure biological safety;

　　(3) meeting the needs of disease prevention and control.

　　The holder of the vaccine marketing license shall have the vaccine production capacity; If it is really necessary to entrust production beyond the vaccine production capacity, it shall be approved by the drug supervision and administration department of the State Council. Those who accept commissioned production shall abide by the provisions of this law and the relevant provisions of the state to ensure the quality of vaccines.

　　Article 23 The legal representative and principal responsible person of the vaccine marketing license holder shall have a good credit record, and the personnel in key positions such as the person in charge of production management, the person in charge of quality management and the person authorized by quality shall have relevant professional background and working experience.

　　The holder of the vaccine marketing license shall strengthen the training and assessment of the personnel specified in the preceding paragraph, and report their positions and changes to the pharmaceutical supervisory and administrative departments of the people’s governments of provinces, autonomous regions and municipalities directly under the Central Government in a timely manner.

　　Article 24 Vaccines shall be produced and inspected according to the approved production technology and quality control standards, and the whole production process shall meet the requirements of good manufacturing practice.

　　The holder of the vaccine marketing license shall, in accordance with the provisions, review and inspect the whole process of vaccine production and vaccine quality.

　　Article 25 The holder of vaccine marketing license shall establish a complete production quality management system, continuously strengthen deviation management, and truthfully record all data formed in the production and inspection process by means of information technology to ensure that the whole production process continues to meet the statutory requirements.

　　Article 26 The State implements the system of batch issuance of vaccines.

　　Before each batch of vaccine is sold or imported, it shall be audited and tested by the batch issuing agency designated by the drug supervision and administration department of the State Council in accordance with the relevant technical requirements. If it meets the requirements, a batch issuance certificate will be issued; Do not meet the requirements, issued a notice of disapproval.

　　Vaccines that are not issued in batches shall not be sold, and shall be destroyed under the supervision of the pharmaceutical supervisory and administrative departments of the people’s governments of provinces, autonomous regions and municipalities directly under the Central Government; The imported vaccines that are not issued in batches shall be destroyed under the supervision of the drug supervision and administration department at the port location or otherwise handled according to law.

　　The State Council pharmaceutical supervisory and administrative departments and batch issuing institutions shall publish the batch issuing results of listed vaccines in time for public inquiry.

　　Article 27 To apply for batch issuance of vaccines, the batch issuing institution shall be provided with the batch production and inspection records, abstracts and other materials, and samples of products with the same batch number. Imported vaccines shall also provide certificates of origin and batch issuance; In case of exemption from batch issuance in the country of origin, a certificate of exemption from batch issuance shall be provided.

　　Twenty-eighth to prevent and control the epidemic situation of infectious diseases or to deal with emergencies, the vaccine is approved by the drug supervision and administration department of the State Council, and is exempted from batch issuance.

　　Twenty-ninth batches of vaccines should be issued batch by batch for data review and sampling inspection. The inspection items and inspection frequency of vaccine batch issuance shall be dynamically adjusted according to the risk assessment of vaccine quality.

　　If there are doubts about the authenticity of the application materials or samples for vaccine batch issuance, or there are other situations that need further verification, the batch issuing institution shall verify them, and if necessary, organize on-site verification by means of on-site sampling inspection.

　　Thirtieth batch issuing institutions found that there are significant quality risks in the process of batch issuance of vaccines, it shall promptly report to the pharmaceutical supervisory and administrative departments of the State Council and the people’s governments of provinces, autonomous regions and municipalities directly under the central government.

　　The department that receives the report shall immediately conduct on-site inspection on the vaccine marketing license holder, notify the batch issuing institution not to approve or suspend the batch issuance of the relevant products or all products of the vaccine marketing license holder according to the inspection results, and order the vaccine marketing license holder to rectify. The holder of the vaccine marketing license shall immediately rectify and report the rectification to the department that ordered it to rectify in time.

　　Article 31 The holder of the vaccine marketing license shall truthfully record the production process deviation, quality difference, faults and accidents in the production process and the measures taken, and specify them in the documents issued by the corresponding batch of products; If the quality of the vaccine may be affected, the holder of the vaccine marketing license shall take immediate measures and report to the pharmaceutical supervisory and administrative departments of the people’s governments of provinces, autonomous regions and municipalities directly under the Central Government.

Chapter IV Vaccine Circulation

　　Article 32 The national immunization program vaccine shall be subject to centralized bidding or unified negotiation by the competent health department of the State Council in conjunction with the financial department of the State Council, and the winning bid price or transaction price shall be formed and announced, and all provinces, autonomous regions and municipalities directly under the Central Government shall implement unified procurement.

　　Other EPI vaccines and non-EPI vaccines other than the national EPI vaccines are purchased by provinces, autonomous regions and municipalities directly under the Central Government through provincial public resource trading platforms.

　　Article 33 The price of vaccine shall be set by the holder of vaccine marketing license independently and reasonably according to law. The price level, price difference rate and profit rate of vaccines should be kept within a reasonable range.

　　Article 34 Provincial institutions for disease prevention and control shall, according to the national immunization program and the needs of disease prevention and control in their respective administrative areas, formulate plans for vaccine use in immunization programs in their respective administrative areas, and report to the departments that organize vaccine procurement in accordance with the relevant provisions of the state, and at the same time report to the health authorities of the people’s governments of provinces, autonomous regions and municipalities directly under the Central Government for the record.

　　Thirty-fifth vaccine marketing license holders should supply vaccines to disease prevention and control institutions in accordance with the procurement contract.

　　Disease prevention and control institutions shall supply vaccines to vaccination units in accordance with regulations.

　　Units and individuals other than disease prevention and control institutions shall not supply vaccines to vaccination units, and vaccination units shall not receive the vaccines.

　　Article 36 The holder of the vaccine marketing license shall distribute the vaccine to the disease prevention and control institution or the inoculation unit designated by the disease prevention and control institution in accordance with the purchase contract.

　　Vaccine marketing license holders and disease prevention and control institutions shall have the conditions for cold chain storage and transportation of vaccines, and may also entrust qualified vaccine distribution units to distribute vaccines.

　　Disease prevention and control institutions can charge storage and transportation fees for the distribution of non-immunization-planned vaccines. The specific measures shall be formulated by the financial department of the State Council in conjunction with the competent price department of the State Council, and the charging standards shall be formulated by the competent price department of the people’s governments of provinces, autonomous regions and municipalities directly under the Central Government in conjunction with the financial department.

　　Thirty-seventh disease prevention and control institutions, vaccination units, vaccine marketing license holders and vaccine distribution units shall abide by the management norms of vaccine storage and transportation to ensure the quality of vaccines.

　　Vaccines should be in the specified temperature environment during the whole process of storage and transportation, and the cold chain storage and transportation should meet the requirements, and the temperature should be monitored and recorded regularly.

　　The management standards for vaccine storage and transportation are jointly formulated by the drug supervision and administration department of the State Council and the health department of the State Council.

　　Article 38 When selling vaccines, the holder of the vaccine marketing license shall provide a copy of the batch issuance certificate or an electronic document stamped with his seal; Sales of imported vaccines, should also provide a copy of the customs clearance form for imported drugs or electronic documents stamped with its seal.

　　Disease prevention and control institutions and vaccination units shall, when receiving or purchasing vaccines, obtain the supporting documents specified in the preceding paragraph and keep them for future reference for not less than five years after the expiration of the vaccine.

　　Article 39 The holder of the vaccine marketing license shall, in accordance with the regulations, establish a true, accurate and complete sales record and keep it for future reference for not less than five years after the expiration of the vaccine.

　　Disease prevention and control institutions, vaccination units and vaccine distribution units shall, in accordance with regulations, establish true, accurate and complete records of receipt, purchase, storage, distribution and supply, and keep them for future reference for not less than five years after the expiration of the vaccine.

　　When the disease prevention and control institutions and inoculation units receive or purchase vaccines, they shall obtain the temperature monitoring records of the whole process of transportation and storage, and keep them for future reference for not less than five years after the expiration of the vaccine; If the temperature monitoring records of the whole transportation and storage process cannot be provided or the temperature control does not meet the requirements, it shall not be accepted or purchased, and it shall immediately report to the pharmaceutical supervisory and administrative department and the health department of the local people’s government at or above the county level.

　　Article 40 Disease prevention and control institutions and inoculation entities shall establish a system of regular inspection of vaccines, and take measures such as isolated storage and setting warning signs for vaccines with unrecognizable packaging, unqualified storage temperature, and expiration date, and dispose of them in accordance with the provisions of the State Council drug supervision and administration department, health department and ecological environment department. Disease prevention and control institutions and vaccination units shall truthfully record the disposal situation, and the disposal records shall be kept for future reference for not less than five years after the expiration of the vaccine.

Chapter V Vaccination

　　Forty-first the State Council health authorities to develop a national immunization program; The types of vaccines under the National Immunization Program shall be drawn up by the competent health department of the State Council in conjunction with the financial department of the State Council, and published after being approved by the State Council.

　　The competent department of health in the State Council established the national immunization program expert advisory committee, and established the dynamic adjustment mechanism of vaccine types in the national immunization program together with the financial department of the State Council.

　　The people’s governments of provinces, autonomous regions and municipalities directly under the Central Government may, when implementing the national immunization program, increase the types of vaccines for immunization programs according to the needs of disease prevention and control in their respective administrative areas, and report them to the health authorities in the State Council for the record and publication.

　　Forty-second the State Council health authorities should formulate and publish vaccination work norms, and strengthen the standardized management of vaccination.

　　The competent department of health in the State Council shall formulate and publish the immunization procedures of the national immunization program vaccine and the guiding principles for the use of the non-immunization program vaccine.

　　The competent health authorities of the people’s governments of provinces, autonomous regions and municipalities directly under the Central Government shall formulate vaccination plans in light of the actual conditions of their respective administrative regions and report them to the competent health authorities of the State Council for the record.

　　Forty-third disease prevention and control institutions at all levels shall, according to their respective responsibilities, carry out publicity, training, technical guidance, monitoring, evaluation, epidemiological investigation and emergency response related to vaccination.

　　Article 44 An inoculation entity shall meet the following conditions:

　　(1) Obtaining the practice license of a medical institution;

　　(2) Having doctors, nurses or rural doctors who have received professional vaccination training organized by the health authorities of the people’s government at the county level and passed the examination;

　　(3) Having cold storage facilities, equipment and a cold storage system that meet the management standards for vaccine storage and transportation.

　　The competent health department of the local people’s government at or above the county level shall designate qualified medical institutions to undertake the immunization program vaccination work in the responsible area. Eligible medical institutions can undertake non-immunization vaccination work, and shall report to the competent health department that issued the practice license of their medical institutions for the record.

　　Vaccination units should strengthen internal management, and carry out vaccination work should abide by vaccination work norms, immunization procedures, vaccine use guidelines and vaccination programs.

　　Disease prevention and control institutions at all levels shall strengthen the technical guidance on vaccination work of vaccination units and the management of vaccine use.

　　Article 45 When carrying out vaccination, medical and health personnel shall inform the recipients or their guardians of the varieties, functions, contraindications, adverse reactions, on-site observation and other matters needing attention, inquire about the health status of the recipients and whether there are any contraindications to vaccination, and record the information truthfully. The recipient or his guardian shall truthfully provide the health status and vaccination contraindications of the recipient. If vaccination is forbidden, medical and health personnel shall give medical advice to the recipient or his guardian, and truthfully record the medical advice.

　　Before vaccination, medical and health personnel should check the health status of the recipients, check the vaccination contraindications, check the vaccination certificate, check the appearance, batch number and expiration date of the vaccine and syringe, check the name and age of the recipients and the name, specification, dosage, vaccination site and vaccination route of the vaccine, and ensure that the recipients, vaccination certificate and vaccine information are consistent before vaccination can be implemented.

　　Medical and health personnel shall vaccinate the recipients who meet the vaccination conditions. In case of adverse reactions of the seed recipients during the on-site observation, medical and health personnel shall take timely treatment and other measures in accordance with the requirements of vaccination work norms.

　　Article 46 Medical and health personnel shall truthfully, accurately and completely record the vaccination information such as the vaccine variety, the identification information of the marketing license holder, the smallest packaging unit, the expiration date, the vaccination time, the medical and health personnel who carried out the vaccination, the recipients, etc. in accordance with the regulations of the health authorities in the State Council, so as to ensure that the vaccination information can be traced and inquired. Vaccination records shall be kept for no less than five years after the expiration of the vaccine.

　　Article 47 The state practices a vaccination certificate system for children. Within one month after a child is born, his guardian shall apply for a vaccination certificate at the vaccination unit or the birth hospital where the child lives. The vaccination unit or the hospital of birth shall not refuse to handle it. The guardian shall properly keep the vaccination certificate.

　　Vaccination shall be administered by the place of residence. During the period when children leave their original place of residence, the vaccination unit undertaking vaccination at the current place of residence shall be responsible for vaccination.

　　The format of vaccination certificate shall be stipulated by the competent health department of the State Council.

　　Article 48 When children enter kindergartens and schools, nursery institutions and schools should check their vaccination certificates. If they find that they have not been vaccinated in accordance with the regulations, they should report to the vaccination unit where the children live or where the nursery institutions and schools are located, and cooperate with the vaccination unit to urge their guardians to replant in accordance with the regulations. Disease prevention and control institutions shall provide technical guidance for kindergartens and schools to check vaccination certificates.

　　Measures for the inspection of children’s nursery and school vaccination certificates shall be formulated by the competent department of health of the State Council in conjunction with the administrative department of education of the State Council.

　　Forty-ninth vaccination units shall not charge any fees for vaccination.

　　Inoculation units can charge vaccination service fees in addition to vaccine fees for non-immunization programs. The charging standards for vaccination service fees shall be formulated by the competent price departments of the people’s governments of provinces, autonomous regions and municipalities directly under the Central Government in conjunction with the financial departments.

　　Article 50 The competent health department of the local people’s government at or above the county level may, according to the information of infectious disease monitoring and early warning, report to the people’s government at the corresponding level for decision and report to the competent health department of the people’s government at or above the provincial level for the record, and carry out mass vaccination in the administrative area.

　　If it is necessary to carry out mass vaccination nationwide or across provinces, autonomous regions and municipalities directly under the Central Government, it shall be decided by the health authorities in the State Council.

　　The local people’s government at or above the county level or the competent department of health in the State Council, which has made the decision on mass vaccination, shall organize the relevant departments to do a good job in personnel training, publicity and education, and material mobilization.

　　No unit or individual may carry out mass vaccination without authorization.

　　Article 51 If the local people’s governments at or above the county level or their health authorities need to take emergency vaccination measures during the outbreak and epidemic of infectious diseases, it shall be implemented in accordance with the provisions of laws and administrative regulations.

Chapter VI Monitoring and Handling of Abnormal Reaction

　　Article 52 The term "abnormal reaction to vaccination" refers to the adverse drug reaction that a qualified vaccine causes damage to the tissues, organs and functions of the recipient during or after the implementation of standardized vaccination, and all parties concerned are not at fault.

　　The following situations do not belong to the abnormal reaction of vaccination:

　　(a) the general reaction after vaccination caused by the characteristics of the vaccine itself;

　　(2) Damage caused to the recipients due to vaccine quality problems;

　　(three) the damage caused to the recipients by the vaccination unit’s violation of the vaccination work norms, immunization procedures, guiding principles for vaccine use, and vaccination programs;

　　(four) the recipient is in the incubation period or precursor period of a disease at the time of inoculation, and the disease is coupled after inoculation;

　　(5) The recipient has vaccination contraindications specified in the vaccine instructions, and the recipient or his guardian failed to truthfully provide the health status and vaccination contraindications of the recipient before vaccination, and the original disease of the recipient has an acute recurrence or aggravation after vaccination;

　　(6) Psychogenic reactions of individuals or groups due to psychological factors.

　　Article 53 The State shall strengthen the monitoring of abnormal reactions to vaccination. The monitoring plan for abnormal reaction of vaccination shall be formulated by the competent health department of the State Council in conjunction with the drug supervision and administration department of the State Council.

　　Fifty-fourth vaccination units, medical institutions and other suspected abnormal reactions to vaccination shall report to the disease prevention and control institutions in accordance with regulations.

　　The holder of the vaccine marketing license shall set up a special institution with full-time staff to actively collect, track and analyze the suspected abnormal vaccination reactions, take timely risk control measures, report the suspected abnormal vaccination reactions to the disease prevention and control institutions, and submit the quality analysis report to the pharmaceutical supervisory and administrative departments of the people’s governments of provinces, autonomous regions and municipalities directly under the Central Government.

　　Article 55 In case of suspected abnormal reaction to vaccination, the disease prevention and control institutions shall report it in time according to the regulations, organize investigation and diagnosis, and inform the recipients or their guardians of the conclusions of the investigation and diagnosis. If the conclusion of the investigation and diagnosis is controversial, you can apply for appraisal according to the appraisal method formulated by the competent department of health in the State Council.

　　Due to vaccination, the recipient dies, is severely disabled, or has a significant impact on the society, such as group suspected vaccination abnormal reaction. The competent health department and drug supervision and administration department of the people’s government at or above the municipal level with districts shall, according to their respective functions and duties, organize investigation and handling.

　　Article 56 The state practices a compensation system for abnormal reactions to vaccination. In the process of vaccination or after vaccination, the recipient’s death, serious disability, organ and tissue damage and other damages are abnormal reactions to vaccination or cannot be ruled out, and compensation should be given. The scope of compensation shall be managed by catalogue and dynamically adjusted according to the actual situation.

　　The compensation expenses required for immunization planning vaccine shall be arranged by the financial departments of the people’s governments of provinces, autonomous regions and municipalities directly under the Central Government in the vaccination funds; The compensation expenses required for vaccination of non-EPI vaccines shall be borne by the holders of relevant vaccine marketing licenses. The state encourages people who have received abnormal vaccination to be compensated through commercial insurance and other forms.

　　Compensation for abnormal reaction of vaccination should be timely, convenient and reasonable. The scope, standards and procedures of compensation for abnormal reaction of vaccination shall be stipulated by the State Council, and the provinces, autonomous regions and municipalities directly under the Central Government shall formulate specific implementation measures.

Chapter VII Post-marketing Management of Vaccines

　　Article 57 The holder of the vaccine marketing license shall establish and improve the quality management system of the whole life cycle of the vaccine, formulate and implement the post-marketing risk management plan of the vaccine, conduct post-marketing research of the vaccine, and further confirm the safety, effectiveness and quality controllability of the vaccine.

　　For vaccines that require further research when approving the application for vaccine registration, the vaccine marketing license holder shall complete the research within the prescribed time limit; If the research is not completed within the time limit or it cannot be proved that the benefits outweigh the risks, the drug supervision and administration department of the State Council shall handle it according to law until the drug registration certificate of the vaccine is cancelled.

　　Fifty-eighth vaccine marketing license holders should carry out quality tracking analysis of vaccines, continuously improve quality control standards, improve production processes, and improve the stability of production processes.

　　If the production process, production site and key equipment are changed, it shall be evaluated and verified, and filed or reported in accordance with the provisions of the drug supervision and administration department of the State Council on change management; Changes that may affect the safety, effectiveness and quality controllability of vaccines shall be approved by the drug supervision and administration department of the State Council.

　　Article 59 The holder of a vaccine marketing license shall continuously update the instructions and labels according to the post-marketing research and abnormal reaction of vaccination, and apply for approval or filing in accordance with regulations.

　　The State Council drug supervision and administration department shall publish the updated vaccine instructions and labels on its website in time.

　　Article 60 The holder of a vaccine marketing license shall establish a system of retrospective analysis and risk reporting of vaccine quality, and truthfully report the production and circulation of vaccine, post-marketing research and risk management to the drug supervision and administration department of the State Council every year according to regulations.

　　Article 61 The drug supervision and administration department of the State Council may, according to the actual situation, order the holder of vaccine marketing license to carry out post-marketing evaluation or directly organize post-marketing evaluation.

　　The drug supervision and administration department of the State Council shall cancel the drug registration certificate of the vaccine that has a serious abnormal reaction to vaccination or is harmful to human health for other reasons.

　　Article 62 The pharmaceutical supervisory and administrative department of the State Council may, according to the needs of disease prevention and control and the development of vaccine industry, organize post-marketing evaluation of vaccine varieties. If it is found that the product design, production process, safety, effectiveness or quality controllability of this vaccine variety are obviously inferior to other vaccine varieties for preventing and controlling the same disease, it shall cancel the drug registration certificates of all vaccines of this variety and abolish the corresponding national drug standards.

Chapter VIII Safeguard Measures

　　Sixty-third people’s governments at or above the county level shall include the funds needed for vaccine safety, purchase of planned vaccines for immunization, vaccination and information construction in the government budget at the corresponding level to ensure the implementation of the immunization planning system.

　　The people’s government at the county level shall, in accordance with the relevant provisions of the state, grant subsidies to rural doctors and other primary medical and health personnel engaged in vaccination work.

　　The state supports vaccination work in economically underdeveloped areas according to needs. The people’s governments of provinces, autonomous regions and municipalities directly under the Central Government and the people’s governments at the municipal level divided into districts shall give necessary financial subsidies to the people’s governments at the county level in economically underdeveloped areas to carry out the work related to vaccination.

　　Article 64 The people’s governments of provinces, autonomous regions and municipalities directly under the Central Government shall, according to the epidemic trend of infectious diseases in their respective administrative areas, determine the projects related to vaccination within the scope of infectious disease prevention and control projects determined by the health authorities in the State Council, and ensure the implementation of the projects.

　　Article 65 The competent health authorities of the State Council shall provide the vaccine marketing license holders with information on the vaccine demand of the national immunization program according to the vaccine use plans of the national immunization programs of all provinces, autonomous regions and municipalities directly under the Central Government, and the vaccine marketing license holders shall make reasonable arrangements for production according to the vaccine demand information.

　　When there is a risk of vaccine supply shortage, the health authorities in the State Council and the drug supervision and administration departments in the State Council put forward suggestions, and the departments in charge of industry and information technology in the State Council and the finance department in the State Council should take effective measures to ensure vaccine production and supply.

　　The holder of vaccine marketing license shall organize production according to law to ensure vaccine supply; If the holder of the vaccine marketing license stops vaccine production, it shall report to the drug supervision and administration department of the State Council or the drug supervision and administration department of the people’s government of a province, autonomous region or municipality directly under the Central Government in time.

　　Article 66 The State shall include vaccines in the strategic material reserve, and implement the reserve at the central and provincial levels.

　　The competent department of industry and information technology in the State Council and the financial department shall, jointly with the health authorities, public security departments, market supervision and management departments and drug supervision and management departments in the State Council, strengthen the production capacity and product management of vaccine reserves and establish a dynamic adjustment mechanism according to the needs of disease prevention, control and public health emergency preparedness.

　　Sixty-seventh financial arrangements at all levels for vaccination funds should be earmarked, and no unit or individual may misappropriate or occupy them.

　　The relevant units and individuals shall accept the audit supervision of audit institutions in accordance with the law when using the funds for vaccination.

　　Article 68 The State implements a compulsory vaccine liability insurance system.

　　The holder of the vaccine marketing license shall take out compulsory vaccine liability insurance in accordance with the regulations. If the vaccine quality problem causes damage to the recipient, the insurance company shall pay compensation within the insured liability limit.

　　The specific measures for the implementation of the compulsory vaccine liability insurance system shall be formulated by the drug supervision and administration department of the State Council in conjunction with the health authorities of the State Council and the insurance supervision and administration institutions.

　　Article 69 When an infectious disease breaks out and is prevalent, the holder of the relevant vaccine marketing license shall timely produce and supply vaccines for preventing and controlling infectious diseases. Transportation units should give priority to the transportation of vaccines for the prevention and control of infectious diseases. The people’s governments at or above the county level and their relevant departments shall do a good job in organization, coordination and guarantee.

Chapter IX Supervision and Administration

　　Article 70 The drug supervision and administration department and the competent health department shall, according to their respective functions and duties, supervise and manage the whole process of vaccine development, production, circulation and vaccination, and supervise the holders of vaccine marketing license, disease prevention and control institutions and vaccination units to perform their obligations according to law.

　　The pharmaceutical supervisory and administrative departments shall supervise and inspect the quality of vaccines in vaccine development, production, storage, transportation and vaccination according to law. Health authorities shall supervise and inspect the implementation of immunization planning system and vaccination activities according to law.

　　The drug supervision and administration department shall strengthen the on-site inspection of vaccine marketing license holders; When necessary, units and individuals that provide products or services for vaccine development, production, circulation and other activities may be subject to extended inspection; The relevant units and individuals shall cooperate and shall not refuse or conceal.

　　Article 71 The state builds a team of professional and specialized drug inspectors at the central and provincial levels, and strengthens the supervision and inspection of vaccines.

　　The pharmaceutical supervisory and administrative departments of the people’s governments of provinces, autonomous regions and municipalities directly under the Central Government shall send inspectors to the holders of vaccine marketing licenses. Inspectors are responsible for supervising and inspecting the implementation of good manufacturing practice, collecting clues about vaccine quality risks and violations of laws and regulations, reporting the situation to the pharmaceutical supervisory and administrative departments of the people’s governments of provinces, autonomous regions and municipalities directly under the Central Government and making suggestions, and being responsible for the behavior during their stationing.

　　Article 72 If there are potential safety hazards in vaccine quality management, and the holder of vaccine marketing license fails to take timely measures to eliminate them, the pharmaceutical supervisory and administrative department may take measures such as responsibility interview and rectification within a time limit.

　　Serious violation of drug-related quality management norms, the drug supervision and administration department shall order the suspension of vaccine production, sales and distribution, and immediately rectify; After the rectification is completed, production, sales and distribution can only be resumed if the drug supervision and administration department checks that it meets the requirements.

　　The drug supervision and administration department shall establish a credit record system for vaccine marketing license holders and their related personnel, incorporate it into the national credit information sharing platform, publicize their serious dishonesty information in accordance with the regulations, and implement joint punishment.

　　Article 73 If there are or are suspected to be quality problems with vaccines, the vaccine marketing license holders, disease prevention and control institutions and inoculation entities shall immediately stop selling, distributing and using, and stop production if necessary, and report to the pharmaceutical supervisory and administrative departments and health authorities of the people’s governments at or above the county level in accordance with regulations. The competent health department shall immediately organize disease prevention and control institutions and inoculation units to take necessary emergency measures and report to the competent health department of the people’s government at a higher level. The pharmaceutical supervisory and administrative department shall take measures such as sealing up and detaining according to law. For vaccines that have been sold, the holder of the vaccine marketing license shall promptly notify the relevant disease prevention and control institutions, vaccine distribution units and inoculation units, recall them in accordance with regulations, and truthfully record the recall and notification, and the disease prevention and control institutions, vaccine distribution units and inoculation units shall cooperate.

　　If the production, sale, distribution, use or recall of vaccines are not stopped in accordance with the provisions of the preceding paragraph, the pharmaceutical supervisory and administrative departments and health authorities of the people’s governments at or above the county level shall, according to their respective functions and duties, order them to stop production, sale, distribution, use or recall of vaccines.

　　Vaccine marketing license holders, disease prevention and control institutions, and vaccination units shall not conceal, falsely report, delay reporting or omit reporting vaccines that have or are suspected to have quality problems, and shall not conceal, forge or destroy relevant evidence.

　　Article 74 The holder of a vaccine marketing license shall establish an information disclosure system, and timely disclose information such as vaccine product information, instructions and labels, implementation of relevant quality management standards for drugs, batch issuance, recall, acceptance of inspection and punishment, and compulsory insurance for vaccine liability on its website in accordance with regulations.

　　Article 75 The drug supervision and administration department of the State Council shall establish an information sharing mechanism on vaccine quality and vaccination together with the health authorities of the State Council.

　　The pharmaceutical supervisory and administrative departments and health authorities of the people’s governments at or above the provincial level shall organize vaccine marketing license holders, disease prevention and control institutions, vaccination units, news media, scientific research units, etc. to exchange information on vaccine quality and vaccination in accordance with the principles of science, objectivity, timeliness and openness.

　　Article 76 The State implements a unified system for publishing vaccine safety information.

　　Vaccine safety risk warning information, major vaccine safety accidents and their investigation and handling information, and other vaccine safety information determined by the State Council that needs to be published uniformly shall be published by the drug supervision and administration department of the State Council jointly with relevant departments. The national report on the abnormal reaction to vaccination shall be uniformly published by the competent health department of the State Council in conjunction with the drug supervision and administration department of the State Council. The above information shall not be released without authorization. The release of major vaccine safety information should be timely, accurate and comprehensive, and scientific evaluation should be made in accordance with the provisions, and necessary explanations should be made.

　　The pharmaceutical supervisory and administrative department of the people’s government at or above the county level shall immediately verify and analyze the vaccine safety information that may mislead the public and public opinion, in conjunction with the health authorities and other relevant departments, professional institutions and relevant vaccine marketing license holders, and publish the results in a timely manner.

　　No unit or individual may fabricate or disseminate false vaccine safety information.

　　Article 77 Any unit or individual has the right to know vaccine information according to law and put forward opinions and suggestions on vaccine supervision and management.

　　Any unit or individual has the right to report vaccine violations to the health authorities, drug supervision and administration departments and other departments, and to report to the people’s government at the same level or higher level and its relevant departments and supervisory organs if the health authorities, drug supervision and administration departments and their staff fail to perform their supervisory and administrative duties according to law. The relevant departments and organs shall promptly verify and deal with it; Reward informants for verified reports in accordance with regulations; Informants who report serious illegal acts of their units and verify them are rewarded handsomely.

　　Article 78 The people’s governments at or above the county level shall formulate emergency plans for vaccine safety incidents, and stipulate the classification of vaccine safety incidents, the organization and command system and responsibilities for handling, the prevention and early warning mechanism, the handling procedures and emergency safeguard measures.

　　The holder of the vaccine marketing license shall formulate a plan for handling vaccine safety incidents, regularly check the implementation of various preventive measures, and eliminate potential safety hazards in time.

　　In the event of a vaccine safety incident, the holder of the vaccine marketing license shall immediately report to the drug supervision and administration department of the State Council or the drug supervision and administration department of the people’s government of a province, autonomous region or municipality directly under the Central Government; Disease prevention and control institutions, vaccination units and medical institutions shall immediately report to the health authorities and drug supervision and administration departments of the people’s governments at or above the county level. The pharmaceutical supervisory and administrative department shall, jointly with the health authorities, set up a command organization for handling vaccine safety incidents in accordance with the provisions of the emergency plan, carry out medical treatment, risk control, investigation and handling, information release, explanation and other work, and do a good job in the aftermath of replanting. The cost of replanting vaccine safety incidents caused by quality problems shall be borne by the holder of vaccine marketing license.

　　The relevant units and individuals shall not conceal, falsely report, delay reporting or omit reporting vaccine safety incidents, and shall not conceal, forge or destroy relevant evidence.

Chapter X Legal Liability

　　Article 79 Whoever violates the provisions of this Law and constitutes a crime shall be severely investigated for criminal responsibility according to law.

　　Article 80 If the vaccines produced and sold belong to counterfeit drugs, the pharmaceutical supervisory and administrative department of the people’s government at or above the provincial level shall confiscate the illegal income, vaccines produced and sold illegally, raw materials, auxiliary materials, packaging materials, equipment and other articles specially used for illegal vaccine production, order it to stop production and business for rectification, revoke the pharmaceutical registration certificate until the pharmaceutical production license is revoked, and impose a fine of not less than 15 times but not more than 50 times the value of vaccines produced and sold illegally. If the value of vaccines is less than 500,000 yuan, it shall be calculated as 500,000 yuan.

　　If the vaccines produced and sold are inferior drugs, the pharmaceutical supervisory and administrative department of the people’s government at or above the provincial level shall confiscate the illegal income and vaccines produced and sold illegally, as well as raw materials, auxiliary materials, packaging materials, equipment and other items specially used for illegal vaccine production, order it to stop production and business for rectification, and impose a fine of not less than 10 times but not more than 30 times the value of vaccines produced and sold illegally. If the value is less than 500,000 yuan, it shall be calculated as 500,000 yuan. If the circumstances are serious, the drug registration certificate shall be revoked until the drug production license is revoked.

　　If the vaccines produced and sold are fake drugs, or the vaccines produced and sold are inferior drugs and the circumstances are serious, the pharmaceutical supervisory and administrative department of the people’s government at or above the provincial level shall confiscate the income earned by the unit during the illegal act, impose a fine of more than one time and less than ten times the income earned, prohibit the pharmaceutical production and business activities for life, and be detained by the public security organ for more than five days and less than fifteen days.

　　Article 81 Under any of the following circumstances, the pharmaceutical supervisory and administrative department of the people’s government at or above the provincial level shall confiscate the illegal income and vaccines illegally produced and sold, as well as raw materials, auxiliary materials, packaging materials, equipment and other articles specially used for illegal vaccine production, order it to stop production and business for rectification, and impose a fine of not less than 15 times but not more than 50 times the value of illegally produced and sold vaccines. If the value is less than 500,000 yuan, it shall be calculated as 500,000 yuan; If the circumstances are serious, the relevant drug approval documents shall be revoked until the drug production license is revoked. The legal representative, principal responsible person, directly responsible person in charge, key position personnel and other responsible personnel shall be confiscated, and they shall be fined more than 50% but less than 10 times of the income earned. They shall be prohibited from engaging in drug production and business activities for ten years until life, and shall be detained by public security organs for more than five days and less than fifteen days:

　　(1) Providing false data, materials, samples or committing other deceptive acts when applying for clinical trials, registration and batch issuance of vaccines;

　　(two) fabricating production and inspection records or changing the batch number of products;

　　(3) Units or individuals other than disease prevention and control institutions supply vaccines to vaccination units;

　　(four) commissioned the production of vaccines without approval;

　　(five) the production process, production site, key equipment and other changes in accordance with the provisions should be approved without approval;

　　(6) Updating vaccine instructions and labels shall be approved without approval according to regulations.

　　Article 82 Unless otherwise provided for in this Law, if the holder of vaccine marketing license or any other unit violates the relevant quality control standards of drugs, the pharmaceutical supervisory and administrative department of the people’s government at or above the county level shall order it to make corrections and give it a warning; Refuses to correct, a fine of two hundred thousand yuan and five hundred thousand yuan; If the circumstances are serious, a fine of not less than 500,000 yuan but not more than 3 million yuan shall be imposed, and the company shall be ordered to suspend production and business for rectification until the relevant drug approval documents and drug production licenses are revoked. The legal representative, principal responsible person, directly responsible person in charge, personnel in key positions and other responsible personnel shall be confiscated from their own units during the illegal act, and a fine of not less than 50% but not more than 5 times shall be imposed, and they shall be prohibited from engaging in drug production and business activities for ten years until life.

　　Article 83 If a holder of a vaccine marketing license violates the provisions of this Law in any of the following circumstances, the pharmaceutical supervisory and administrative department of the people’s government at or above the provincial level shall order him to make corrections and give him a warning; Refuses to correct, a fine of two hundred thousand yuan and five hundred thousand yuan; If the circumstances are serious, it shall be ordered to suspend production and business for rectification, and a fine of not less than 500,000 yuan but not more than 2 million yuan shall be imposed:

　　(1) Failing to establish an electronic traceability system for vaccines as required;

　　(two) the legal representative, the main person in charge, the person in charge of production management, the person in charge of quality management, the quality authorized person and other key positions do not meet the prescribed conditions or fail to carry out training and assessment in accordance with the provisions;

　　(3) Failing to report or put on record as required;

　　(4) Failing to carry out post-marketing research in accordance with the regulations, or failing to set up institutions and staff in accordance with the regulations to actively collect, track and analyze suspected abnormal reactions to vaccination;

　　(5) Failing to take out compulsory vaccine liability insurance as required;

　　(six) the information disclosure system is not established in accordance with the provisions.

　　Article 84 If a batch issuing institution violates the provisions of this Law in any of the following circumstances, the drug supervision and administration department of the State Council shall order it to make corrections and give it a warning, and the principal responsible person, the directly responsible person in charge and other directly responsible personnel shall be given a warning according to law until demotion:

　　(1) Failing to conduct examination and inspection in accordance with the provisions;

　　(2) Failing to announce the results of batch issuance of vaccines on the market in time;

　　(3) Failing to verify in accordance with the provisions;

　　(4) Failing to report the major quality risks of the vaccine as required.

　　If, in violation of the provisions of this Law, the batch issuing institution fails to issue a batch issuing certificate or refuses to issue a batch issuing notice in accordance with the provisions, the drug supervision and administration department of the State Council shall order it to make corrections, give it a warning, and demote or dismiss the principal responsible person, the directly responsible person in charge and other directly responsible personnel according to law; If the circumstances are serious, the principal responsible person, the directly responsible person in charge and other directly responsible personnel shall be dismissed according to law.

　　Article 85 If disease prevention and control institutions, inoculation units, vaccine marketing license holders and vaccine distribution units violate the requirements of cold chain storage and transportation in the management norms for vaccine storage and transportation, the pharmaceutical supervisory and administrative department of the people’s government at or above the county level shall order them to make corrections, give them a warning, destroy the illegally stored and transported vaccines and confiscate their illegal income; Refuses to correct, the vaccination units, vaccine marketing license holders, vaccine distribution units at more than two hundred thousand yuan to one million yuan fine; If the circumstances are serious, the vaccination units, vaccine marketing license holders and vaccine distribution units shall be fined for illegally storing and transporting vaccines for more than 10 times and less than 30 times. If the value is less than 100,000 yuan, the vaccine marketing license holders and vaccine distribution units shall be ordered to stop production and suspend business for rectification until the relevant approval documents and drug production licenses are revoked, and the legal representatives, principals and direct responsibilities of the vaccine marketing license holders and vaccine distribution units shall be directly responsible.

　　If the disease prevention and control institutions and inoculation units commit illegal acts as prescribed in the preceding paragraph, the competent health department of the people’s government at or above the county level shall give a warning to the main person in charge, the directly responsible person in charge and other directly responsible personnel according to law until they are dismissed, and order the responsible medical and health personnel to suspend their practice activities for more than one year and less than 18 months; If serious consequences are caused, the principal responsible person, the directly responsible person in charge and other directly responsible personnel shall be dismissed according to law, and the inoculation qualification of the inoculation unit may be revoked, and the practice certificate of the responsible medical and health personnel shall be revoked by the original issuing department.

　　Article 86 If disease prevention and control institutions, inoculation entities, vaccine marketing license holders and vaccine distribution entities violate the management norms of vaccine storage and transportation other than those specified in Article 85 of this Law, the pharmaceutical supervisory and administrative department of the people’s government at or above the county level shall order them to make corrections, give them a warning and confiscate their illegal income; Refuses to correct, the vaccination units, vaccine marketing license holders, vaccine distribution units at more than one hundred thousand yuan to three hundred thousand yuan fine; If the circumstances are serious, the vaccination unit, vaccine marketing license holder and vaccine distribution unit shall be fined for illegally storing and transporting vaccines with a value of more than three times and less than ten times. If the value is less than 100,000 yuan, it shall be calculated as 100,000 yuan.

　　If the disease prevention and control institutions and vaccination units commit illegal acts as prescribed in the preceding paragraph, the health department of the people’s government at or above the county level may give warning to the principal responsible person, the directly responsible person in charge and other directly responsible personnel according to law until dismissal, and order the responsible medical and health personnel to suspend their practice activities for more than six months and less than one year; If serious consequences are caused, the principal responsible person, the directly responsible person in charge and other directly responsible personnel shall be dismissed according to law, and the practice certificate of the responsible medical and health personnel shall be revoked by the original issuing department.

　　Article 87 If a disease prevention and control institution or vaccination unit violates the provisions of this Law in any of the following circumstances, the competent health department of the people’s government at or above the county level shall order it to make corrections, give it a warning and confiscate its illegal income; If the circumstances are serious, the principal responsible person, the directly responsible person in charge and other directly responsible personnel shall be given a warning until dismissal, and the responsible medical and health personnel shall be ordered to suspend their practice activities for more than one year and less than 18 months; If serious consequences are caused, the principal responsible person, the directly responsible person in charge and other directly responsible personnel shall be dismissed according to law, and the practice certificate of the responsible medical and health personnel shall be revoked by the original issuing department:

　　(1) Failing to supply, receive or purchase vaccines as required;

　　(two) vaccination did not comply with the vaccination work norms, immunization procedures, vaccine use guidelines, vaccination program;

　　(three) unauthorized mass vaccination.

　　Article 88 If a disease prevention and control institution or vaccination unit violates the provisions of this Law in any of the following circumstances, the competent health department of the people’s government at or above the county level shall order it to make corrections and give it a warning; If the circumstances are serious, the principal responsible person, the directly responsible person in charge and other directly responsible personnel shall be given a warning until dismissal, and the responsible medical and health personnel shall be ordered to suspend their practice activities for more than six months and less than one year; If serious consequences are caused, the principal responsible person, the directly responsible person in charge and other directly responsible personnel shall be dismissed according to law, and the practice certificate of the responsible medical and health personnel shall be revoked by the original issuing department:

　　(1) Failing to provide traceability information as required;

　　(2) Failing to obtain and keep relevant certification documents and temperature monitoring records in accordance with regulations when receiving or purchasing vaccines;

　　(3) Failing to establish and keep records of vaccine receipt, purchase, storage, distribution, supply, inoculation and disposal in accordance with regulations;

　　(4) Failing to inform or ask the recipient or his guardian about the situation in accordance with the regulations.

　　Article 89 If disease prevention and control institutions, vaccination units and medical institutions fail to report suspected abnormal vaccination reactions and vaccine safety incidents in accordance with regulations, or fail to organize investigation and diagnosis of suspected abnormal vaccination reactions in accordance with regulations, the competent health department of the people’s government at or above the county level shall order them to make corrections and give them a warning; If the circumstances are serious, the vaccination units and medical institutions shall be fined between 50,000 yuan and 500,000 yuan, and the principal responsible persons, directly responsible personnel in charge and other directly responsible personnel of the disease prevention and control institutions, vaccination units and medical institutions shall be given a warning according to law until dismissal; If serious consequences are caused, the principal responsible person, the directly responsible person in charge and other directly responsible personnel shall be dismissed according to law, and the practice certificate of the responsible medical and health personnel shall be revoked by the original issuing department.

　　Article 90 If a disease prevention and control institution or vaccination unit collects fees in violation of the provisions of this Law, the competent health department of the people’s government at or above the county level shall supervise it to return the illegally collected fees to the unit or individual who originally paid the fees, and the market supervision and management department of the people’s government at or above the county level shall punish it according to law.

　　Article 91 Anyone who, in violation of the provisions of this Law, engages in immunization planning vaccination without being designated by the competent health department of the local people’s government at or above the county level, or engages in non-immunization planning vaccination that does not meet the requirements or has not been put on record, shall be ordered by the competent health department of the people’s government at or above the county level to make corrections, give a warning, confiscate the illegal income and illegally held vaccines, be ordered to suspend business for rectification, and be fined not less than 100,000 yuan but not more than 1 million yuan. The principal responsible person, the directly responsible person in charge and other directly responsible personnel shall be punished according to law.

　　In violation of the provisions of this law, units or individuals other than disease prevention and control institutions and vaccination units carry out mass vaccination without authorization, and the health authorities of the people’s governments at or above the county level shall order them to make corrections, confiscate the illegal income and illegally held vaccines, and impose a fine of not less than 10 times but not more than 30 times the value of illegally held vaccines. If the value is less than 50,000 yuan, it shall be calculated as 50,000 yuan.

　　Ninety-second guardians who fail to ensure that school-age children are vaccinated on time according to law shall be criticized and educated by the health authorities of the people’s government at the county level and ordered to make corrections.

　　Nursery institutions and schools that fail to check vaccination certificates in accordance with the regulations when children enter kindergartens and schools, or fail to report to the vaccination unit after discovering children who have not been vaccinated in accordance with the regulations, the education administrative department of the local people’s government at or above the county level shall order them to make corrections, give them a warning, and punish the principal responsible person, the directly responsible person in charge and other directly responsible personnel according to law.

　　Article 93 Whoever fabricates or disseminates false vaccine safety information, or makes trouble in the inoculation unit, which constitutes a violation of public security administration, shall be punished by the public security organ according to law.

　　Newspapers, periodicals, radio, television, Internet sites and other media fabricate and disseminate false information about vaccine safety, and the relevant departments shall punish them according to law, and the principal responsible person, the directly responsible person in charge and other directly responsible personnel shall be punished according to law.

　　Article 94 If the local people’s governments at or above the county level have any of the following circumstances in vaccine supervision and management, the directly responsible person in charge and other directly responsible personnel shall be demoted or dismissed according to law; If the circumstances are serious, he shall be dismissed according to law; Causing serious consequences, the main person in charge shall resign:

　　(a) ineffective performance of duties, resulting in serious adverse effects or heavy losses;

　　(2) Concealing, misrepresenting, delaying or omitting vaccine safety incidents;

　　(3) Interfering with or obstructing the investigation of vaccine violations or vaccine safety incidents;

　　(four) a particularly serious vaccine safety accident occurred in the administrative area, or a series of major vaccine safety accidents occurred.

　　Article 95 If the drug supervision and administration department, health department and other departments have any of the following circumstances in vaccine supervision and management, the directly responsible person in charge and other directly responsible personnel shall be demoted or dismissed according to law; If the circumstances are serious, he shall be dismissed according to law; Causing serious consequences, the main person in charge shall resign:

　　(a) failing to perform the duties of supervision and inspection, or failing to investigate and deal with illegal acts in time;

　　(two) unauthorized mass vaccination;

　　(3) Concealing, misrepresenting, delaying or omitting vaccine safety incidents;

　　(4) Interfering with or obstructing the investigation of vaccine violations or vaccine safety incidents;

　　(5) divulging the information of informants;

　　(six) received a report on the suspected abnormal reaction to vaccination, and failed to organize the investigation and handling in accordance with the provisions;

　　(seven) other acts that fail to perform the duties of vaccine supervision and management, resulting in serious adverse effects or heavy losses.

　　Article 96 If the vaccine quality problem causes damage to the recipients, the holder of the vaccine marketing license shall be liable for compensation according to law.

　　Disease prevention and control institutions and vaccination units that violate vaccination work norms, immunization procedures, guiding principles for the use of vaccines, and vaccination programs, causing damage to the recipients, shall be liable for compensation according to law.

Chapter XI Supplementary Provisions

　　Article 97 The meanings of the following terms in this Law are:

　　Immunization vaccines refer to vaccines that residents should be vaccinated in accordance with government regulations, including vaccines determined by the national immunization program, vaccines added by the people’s governments of provinces, autonomous regions and municipalities directly under the Central Government when implementing the national immunization program, and vaccines used for emergency vaccination or mass vaccination organized by the people’s governments at or above the county level or their health authorities.

　　Non-EPI vaccines refer to other vaccines voluntarily vaccinated by residents.

　　The holder of vaccine marketing license refers to an enterprise that has obtained the registration certificate of vaccine drugs and the drug production license according to law.

　　Article 98 The State encourages vaccine production enterprises to produce and export vaccines in accordance with international procurement requirements.

　　The exported vaccine shall meet the standards or contract requirements of the importing country (region).

　　Article 99 Entry-exit vaccination and procurement of required vaccines shall be separately stipulated by the frontier health and quarantine organ in consultation with the financial department of the State Council.

　　Article 100 This Law shall come into force as of December 1, 2019.

　　China. com, April 9 (Xinhua) Recently, the Insurance Regulatory Commission of the Bank of China (hereinafter referred to as "China Banking and Insurance Regulatory Commission") issued a notice on the in-depth management of chaos in the life insurance market, and made it clear that the typical problems and key risks in the life insurance market, such as misleading sales and alienated products, will be specially managed around sales behavior, personnel management, data authenticity and internal control.

　　The notice made it clear that in terms of sales behavior, we will focus on misleading consumers, alienating products, mismanagement and other behaviors in the sales process; In terms of personnel management, we will focus on the management of personnel fraud, loose disorder and other behaviors, including false information, inflated manpower, untrustworthy personnel, loose management and so on; In the aspect of data authenticity, we should focus on the behaviors such as false underwriting, false listing of expenses, false hanging of business, false hanging of people’s heads to get funds, and secret payment of handling fees outside the account. In terms of internal control, it focuses on the problems existing in business control, financial control, performance of duties by senior executives, risk management and internal supervision.

　　This special work was carried out from April 2021 to November 2021, and it was divided into two stages: self-examination and self-correction of institutions and spot checks of supervision. In the stage of self-examination and self-correction, the head office of life insurance company organizes branches at all levels to carry out self-examination and self-correction one by one according to the key points of governance. In the spot check stage, the Banking Insurance Regulatory Bureau, in accordance with the requirements of China Banking and Insurance Regulatory Commission, China, selected no less than three branches at the provincial level and below to carry out on-site inspections based on daily supervision and self-examination and self-correction of branches, and handled them according to laws and regulations.

　　The notice stressed that the Banking Insurance Regulatory Bureau should scientifically arrange the entry time, pay close attention to the links and fields with high and frequent violations of laws and regulations, and conduct on-site inspections according to laws and regulations to ensure that the inspection facts are clear, the evidence is complete, the qualitative is accurate and the basis is appropriate. It is necessary to carry out the necessary extended inspection on the problems found in the inspection involving intermediary business, and investigate the institutions involved and the responsible personnel together. It is necessary to find and investigate violations of laws and regulations, seriously investigate the responsibilities of institutions and related responsible personnel, and give administrative penalties or take corresponding regulatory measures according to law; Anyone who meets the transfer criteria will be resolutely transferred to public security, judicial and supervisory organs.